On this page
Quick Reference
Overview and Recommendations
Background
- •Gout is a chronic crystal deposition disease characterized by acute inflammatory arthritis triggered by monosodium urate (MSU) crystals in joints and periarticular tissues, arising from supersaturation of extracellular fluid with urate (serum threshold >6.8 mg/dL).
- •It affects approximately 9.2 million US adults (3.9% prevalence) and is the most common inflammatory arthritis in men over 40, with rising global prevalence paralleling obesity and metabolic syndrome epidemics.
- •Untreated, gout progresses from episodic self-limited flares to chronic tophaceous arthritis with irreversible bone erosions; excess mortality is driven by cardiovascular disease (HR 1.58 for CVD events).
- •The central pathophysiology involves the NLRP3 inflammasome: MSU crystals are phagocytosed by macrophages, triggering lysosomal rupture and caspase-1 activation, which cleaves pro-IL-1β into active IL-1β — the master cytokine of the acute flare.
- •Major risk factors include hyperuricemia (RR 13.6 for SU ≥9 mg/dL vs <6), genetic variants in urate transporters (SLC2A9, ABCG2), obesity (RR 2.3), alcohol intake (RR 2.5), and diuretic use (RR 2.0).
Evaluation
- •Suspect gout in any patient with acute, self-limited monoarthritis — especially first metatarsophalangeal joint (podagra) — with rapid onset (<12 hours) of severe pain, erythema, and swelling.
- •Ask about prior similar episodes (recurrent podagra has LR+ 4.3), family history of gout, dietary triggers (purine-rich foods, alcohol, fructose-sweetened beverages), and medications (thiazides, low-dose aspirin, cyclosporine).
- •Examine the affected joint: shiny, erythematous, warm, exquisitely tender to even light touch (bedsheet pain). Assess for tophi (firm subcutaneous nodules at helix, olecranon bursa, Achilles tendon) and chronic arthropathy (limited ROM, crepitus).
- •Perform arthrocentesis for synovial fluid analysis — gold standard. Send fluid for polarized light microscopy (negatively birefringent needle-shaped MSU crystals), Gram stain, culture, and cell count (WBC >50,000/μL raises concern for septic arthritis).
- •If crystals are not found but suspicion remains, use the 2015 ACR/EULAR classification criteria: score ≥8 points from clinical (typical podagra, MTP involvement), laboratory (serum urate ≥8 mg/dL), and imaging domains (ultrasound double contour sign or DECT urate deposition).
- •Order serum urate measurement — but note it can be normal during an acute flare in up to 40% of patients; recheck at least 2 weeks after flare resolution for baseline.
- •Check baseline renal function (eGFR), liver enzymes, and CBC before initiating urate-lowering therapy.
- •Consider HLA-B*5801 genotyping in patients of Han Chinese, Thai, Korean, or African American descent before starting allopurinol (risk of hypersensitivity syndrome; OR ~80).
- •Perform ultrasound of symptomatic and contralateral first MTP joints: look for double contour sign (hyperechoic band over cartilage), tophus, aggregates, and bone erosion.
- •If ultrasound is equivocal, consider dual-energy CT (DECT) of feet and knees — sensitivity 87%, specificity 84% — particularly useful for deep tophi and monitoring urate burden.
- •Exclude septic arthritis in any acute monoarthritis with fever >38.5°C, rigors, or risk factors (immunosuppression, prosthetic joint).
Management
- •For acute flares, initiate therapy within 24 hours: NSAIDs (indomethacin 50 mg TID or naproxen 500 mg BID for 5-7 days) with PPI if at GI risk; or low-dose colchicine (1.2 mg at first sign, then 0.6 mg one hour later, followed by 0.6 mg BID for a few days); or corticosteroids (prednisone 30-35 mg daily for 5 days; no taper needed).
- •Avoid high-dose colchicine (e.g., 1.2 mg every hour) due to dose-dependent GI toxicity without added efficacy.
- •For refractory flares or contraindications to first-line agents, use IL-1 inhibitors: canakinumab 150 mg SC single dose (approved in Europe) or anakinra 100 mg SC daily for 3-5 days (off-label).
- •For severe polyarticular flares unable to tolerate oral therapy, consider IV methylprednisolone 40-80 mg daily for 3-5 days.
- •Initiate urate-lowering therapy (ULT) for any patient with ≥2 flares/year, tophi, erosive disease on imaging, or stage ≥3 CKD (eGFR <60 mL/min/1.73 m²). ULT can be started during an acute flare if adequate anti-inflammatory coverage is provided.
- •First-line ULT is allopurinol: start at 100 mg daily (50 mg if eGFR <30 mL/min/1.73 m²), escalate by 100 mg every 2-4 weeks to target serum urate <6 mg/dL (or <5 mg/dL if tophaceous), up to maximum 800 mg daily.
- •If allopurinol fails or is not tolerated, alternatives include febuxostat 40-80 mg daily (caution in patients with prior CV disease; CARES trial showed increased CV death, but FAST trial found non-inferiority for MACE), probenecid 250-1000 mg BID (avoid if eGFR <30), or benzbromarone 50-200 mg daily (monitor LFTs for hepatotoxicity).
- •For patients who fail two oral agents, add a uricosuric (probenecid or benzbromarone) to a xanthine oxidase inhibitor before considering pegloticase.
- •Pegloticase 8 mg IV every 2 weeks is reserved for severe tophaceous gout refractory to oral ULT; co-administer with methotrexate 15 mg weekly to improve response rates (71% vs 41%) and reduce infusion reactions (13% vs 30%).
- •During ULT initiation, provide flare prophylaxis for at least 3-6 months: colchicine 0.5-0.6 mg daily (or 1 mg/day if tolerated and eGFR >30), low-dose NSAID (naproxen 250 mg BID with PPI if needed), or prednisone ≤10 mg/day if contraindications to both.
- •Monitor serum urate every 2-4 weeks during dose escalation, then every 6-12 months once target is achieved. Also monitor renal function, LFTs, and CBC.
- •Do not use fixed low doses of allopurinol (e.g., 100-300 mg without escalation) — a dose-escalation strategy to target is strongly recommended.
- •Do not treat asymptomatic hyperuricemia with pharmacologic ULT — no evidence of benefit and risk of adverse effects.
- •Refer to rheumatology if ULT target is not achieved after 3 months, if there are multiple drug intolerances, if tophi are refractory, or if the patient has severe erosive or tophaceous disease.
- •Discharge criteria for inpatient gout flares: pain controlled with oral medications, fever resolved (if septic arthritis excluded), and ability to bear weight or perform activities of daily living.
Board Review — High Yield
- •Podagra — First MTP joint involvement, LR+ 4.3 for gout
- •Double contour sign — Hyperechoic band over cartilage on ultrasound; sensitivity 83%, specificity 76%
- •NLRP3 inflammasome — Central to gout pathogenesis; MSU crystals trigger IL-1β release
- •HLA-B*5801 — Strongly associated with allopurinol hypersensitivity (OR ~80); test in Asian and African American patients
- •Treat-to-target — SU <6 mg/dL (<5 if tophaceous); GO TEST Overture trial showed superiority over symptom-driven care
- •Pegloticase + methotrexate — Improves responder rates from 41% to 71%; reduces infusion reactions
- •Colchicine prophylaxis — First 3-6 months of ULT; low-dose (0.5-0.6 mg daily) reduces flares by ~50%
- •CARES vs FAST trials — CARES found febuxostat increased CV death (HR 1.34); FAST found non-inferiority for MACE; avoid febuxostat in patients with prior MI/stroke
- •LOCOL trial — Colchicine 0.5 mg daily non-inferior to placebo for flare prophylaxis? No, but still halved flares
- •G-CAN remission — No flares in 12 months, no tophi, SU <6 mg/dL
Deep Dive — Evidence Details
Definition, Classification & Nomenclature
- ▸Gout is a crystal deposition disease caused by monosodium urate crystals, with standardized nomenclature from G-CAN defining disease states from asymptomatic hyperuricemia to chronic tophaceous gout.
- ▸Classification is based on etiology (primary vs secondary) and clinical stage; the 2015 ACR/EULAR criteria are the research standard but definitive diagnosis requires crystal identification.
- ▸Gout is the most common inflammatory arthritis in men, with rising global prevalence and strong associations with cardiovascular and renal comorbidities.
Gout is a chronic crystal deposition disease characterized by episodes of acute inflammatory arthritis triggered by the formation of monosodium urate (MSU) crystals in joints and periarticular tissues [15]D5[36]D5. Also called gouty arthritis, urate crystal arthritis, and historically podagra when the first metatarsophalangeal joint is involved, the condition arises from supersaturation of extracellular fluid with urate, leading to crystal nucleation and an intense -mediated inflammatory response [13]D5[17]C4.
Nomenclature and Disease States
The Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) has standardized the nomenclature for disease states to ensure consistent communication across clinical and research settings [15]D5. The recognized phases are:
- Asymptomatic hyperuricemia: elevated serum urate without clinical evidence of MSU crystal deposition or arthritis.
- Acute gout flare: sudden onset of severe joint pain, swelling, erythema, and tenderness, typically reaching peak intensity within 12–24 hours [20]B2b.
- Intercritical gout: symptom-free periods between flares, during which MSU crystals may persist in synovial fluid.
- Chronic gouty arthritis: persistent joint inflammation and damage due to ongoing crystal deposition.
- Tophaceous gout: presence of subcutaneous or intraosseous collections of MSU crystals (tophi), often associated with chronic disease and joint deformity [15]D5. The G-CAN common language definition describes gout as "a form of arthritis caused by too much uric acid in the body" that can form "needle-like crystals in a joint and cause sudden, severe pain, tenderness, redness, warmth, and swelling" [36]D5.
Classification of Gout
Gout is classified along two main axes: etiology and clinical stage. The 2015 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria are the current standard for research classification, requiring a total score ≥8 points from clinical, laboratory, and imaging domains [2]A1c[6]A1c. These criteria are distinct from diagnostic criteria; definitive diagnosis requires identification of MSU crystals in synovial fluid or tophus aspirate [2]A1c[24]B2b.
| Clinical Stage | Key Features | Typical Serum Urate |
|---|---|---|
| Asymptomatic hyperuricemia | No symptoms; incidental lab finding | >6.8 mg/dL (0.41 mmol/L) |
| Acute gout flare | Monoarticular or oligoarticular arthritis; self-limited (3–14 days) | Often elevated but can be normal during flare |
| Intercritical gout | No active inflammation; may have subclinical crystal deposition | Variable |
| Chronic tophaceous gout | Persistent synovitis, tophi, bone erosions | Persistently elevated |
Etiologically, gout is divided into primary (idiopathic or genetic, often due to underexcretion or overproduction of urate) and secondary (due to acquired causes such as diuretic use, chronic kidney disease, myeloproliferative disorders, or high-purine diet) [22]B3b[31]D5. The majority of cases are primary, with heritability estimates of 30–40% and multiple loci (e.g., SLC2A9, ABCG2) influencing serum urate levels [5]B3b.
Clinical Significance
Gout is the most common cause of inflammatory arthritis in men, with a rising global prevalence that parallels the epidemics of obesity and metabolic syndrome [4]B2c[31]D5. It is strongly associated with cardiovascular disease, chronic kidney disease, , and diabetes, and carries an increased risk of all-cause and cardiovascular mortality [7]B2b[31]D5. The disease imposes a substantial burden on healthcare systems, with hospitalizations and emergency department visits increasing over the past decade [27]B2c.
Pearl: Gout is defined by MSU crystal deposition; the G-CAN nomenclature provides standardized labels for disease states, and the 2015 ACR/EULAR criteria offer validated classification for research [2]A1c[15]D5.
Pathophysiology & Mechanism
- ▸Hyperuricemia is predominantly due to renal underexcretion driven by genetic variants in urate transporters such as SLC2A9, ABCG2, and SLC22A12 [39,56].
- ▸MSU crystals activate the NLRP3 inflammasome via lysosomal rupture and cathepsin release, leading to IL-1β secretion as the master cytokine of acute flares [43,51,68].
- ▸Spontaneous resolution involves neutrophil apoptosis, anti-inflammatory cytokines, and crystal coating by apolipoproteins [61,62].
The pathogenesis of gout proceeds through three obligate steps: sustained hyperuricemia, monosodium urate (MSU) crystal deposition, and an innate immune response to those crystals [54]D5.
Hyperuricemia: The Metabolic Prerequisite
Hyperuricemia arises from an imbalance between urate production and excretion. Overproduction accounts for ~10% of cases, often due to purine-rich diet, alcohol, or genetic defects in purine metabolism. The remaining 90% result from renal underexcretion, driven by polymorphisms in urate transporters such as SLC2A9 (GLUT9), ABCG2, and SLC22A12 (URAT1) [39]B3b[56]D5. Serum urate concentration >6.8 mg/dL (the solubility threshold) creates supersaturation, the thermodynamic prerequisite for crystal nucleation [54]D5. Drug-induced hyperuricemia (e.g., thiazides, , low-dose ) affects up to 25% of hospitalized patients and >80% of transplant recipients [65]D5.
MSU Crystal Formation and Deposition
Supersaturation alone is insufficient; nucleation requires a nidus. Cartilage matrix components, such as proteoglycans and collagen fragments released during joint injury or osteoarthritis, accelerate crystallization [42]D5. The absence of lubricin, a natural inhibitor of crystal formation, further promotes deposition in damaged joints [42]D5. Crystals deposit preferentially in articular cartilage, synovium, and periarticular tissues, forming tophi over time. Imaging studies confirm that joint damage precedes and facilitates crystal deposition, creating a vicious cycle [42]D5.
The Inflammasome and IL-1β Axis
MSU crystals are recognized as danger-associated molecular patterns (DAMPs) by the innate immune system. They engage Toll-like receptors (TLR2 and TLR4) on macrophages, priming the cell for pro-IL-1β transcription via NF-κB [53]D5[60]D5. Simultaneously, crystal phagocytosis triggers lysosomal rupture, releasing cathepsins that activate the NLRP3 inflammasome [68]D5. NLRP3 oligomerizes with ASC and pro-caspase-1, leading to caspase-1 cleavage and processing of pro-IL-1β into its active form [43]D5[51]D5. Active IL-1β is the master cytokine of the acute flare, inducing vasodilation, neutrophil recruitment, and secondary release of IL-6, TNF-α, and chemokines [51]D5[53]D5. Soluble uric acid itself primes TLR responses by inhibiting IL-1 receptor antagonist (IL-1Ra), amplifying the inflammatory cascade [46]D5.
Neutrophil Recruitment and NETosis
IL-1β-driven chemokine secretion recruits neutrophils to the joint within hours. Neutrophils phagocytose MSU crystals, releasing reactive oxygen species and proteolytic enzymes that cause tissue damage [59]D5. A hallmark of gout is the formation of neutrophil extracellular traps (NETs) — webs of decondensed chromatin and antimicrobial proteins — which ensnare crystals but also amplify inflammation [59]D5[66]D5. NETs contribute to chronic synovitis and tophus formation by providing a scaffold for further crystal deposition [66]D5. Pyroptosis, a lytic form of programmed cell death mediated by gasdermin D, also occurs in macrophages and releases IL-1β and DAMPs, perpetuating the cycle [67]D5.
Resolution of Acute Inflammation
Acute gout flares are self-limiting, typically resolving within 7–10 days even without treatment [61]D5. Resolution involves several mechanisms: (1) neutrophil apoptosis and efferocytosis by macrophages, which switch to an anti-inflammatory M2 phenotype; (2) release of anti-inflammatory cytokines such as IL-10 and TGF-β; (3) coating of MSU crystals by apolipoprotein B and other proteins that reduce their inflammatory potential; and (4) activation of peroxisome proliferator-activated receptor γ (PPARγ) and other nuclear receptors that suppress NF-κB [61]D5[62]D5. The spontaneous resolution explains why many patients do not seek medical attention for early flares.
Joint Damage and Chronic Gout
Recurrent flares and persistent crystal deposition lead to chronic inflammation, bone erosion, and cartilage loss. MSU crystals directly stimulate osteoclastogenesis via RANKL upregulation and inhibit osteoblast function, causing juxta-articular erosions with overhanging edges (the "rat-bite" lesion) [55]D5. Chondrocytes exposed to crystals produce matrix metalloproteinases and nitric oxide, degrading cartilage [55]D5. Tophi, composed of crystalline cores surrounded by a granulomatous reaction of macrophages and giant cells, cause structural damage and deformities [55]D5.
Genetic and Epigenetic Modifiers
Genome-wide association studies have identified >30 loci for serum urate levels, with the strongest effects in SLC2A9, ABCG2, and SLC22A12 [39]B3b[56]D5. The transition from hyperuricemia to gout also involves inflammatory genes: variants in NLRP3, IL1B, and CARD8 modulate inflammasome activity [54]D5[56]D5. Epigenome-wide studies reveal differential DNA methylation at immune-related genes in gout patients compared with hyperuricemic controls, suggesting that epigenetic reprogramming of monocytes contributes to the break in tolerance [54]D5. Mendelian randomization confirms causal roles for circulating inflammatory proteins such as FGF-21, MMP-1, and G-CSF in gout pathogenesis [64]B2c.
| Genetic Locus | Gene Product | Function | Effect on Gout Risk |
|---|---|---|---|
| SLC2A9 | GLUT9 | Urate reabsorption in kidney | Strongest association with serum urate [39]B3b[56]D5 |
| ABCG2 | Breast cancer resistance protein | Urate secretion in kidney and gut | Loss-of-function increases risk [39]B3b[56]D5 |
| SLC22A12 | URAT1 | Urate reabsorption in proximal tubule | Gain-of-function increases risk [39]B3b |
| NLRP3 | NLRP3 | Inflammasome sensor | Variants modulate IL-1β release [54]D5 |
Pearl: Gout is a three-step disease: hyperuricemia → MSU crystal deposition → NLRP3 inflammasome-driven IL-1β release. Understanding this cascade explains why urate-lowering therapy prevents flares (by removing the substrate) and why IL-1 blockade is effective in acute attacks [51]D5[54]D5.
Epidemiology, Etiology & Risk Factors
- ▸Global gout prevalence increased 22.5% from 1990 to 2020, affecting 55.8 million people in 2020.
- ▸Incidence ranges from 0.58 to 2.89 per 1,000 person-years, with highest rates in Pacific Islanders, Māori, and African Americans.
- ▸Key modifiable risk factors include hyperuricemia (RR 13.6 for ≥9.0 mg/dL), obesity (RR 2.3), alcohol (RR 2.5), and diuretic use (RR 2.0); genetic variants in SLC2A9 and ABCG2 confer ORs of 1.6–1.7.
Gout affects 55.8 million people globally, with an age-standardized prevalence that increased 22.5% between 1990 and 2020 [100]B2c. The global prevalence in 2020 was 0.53% (95% UI 0.44–0.63), and the number of prevalent cases rose from 33.5 million in 1990 to 55.8 million in 2020 [100]B2c. Incidence ranges from 0.58 to 2.89 per 1,000 person-years across populations, with higher rates in men and older adults [116]D5. In the United States, the prevalence among adults is 3.9% (approximately 9.2 million individuals), with a male predominance (5.2% vs 2.7% in women) [93]C4[115]C4. Within the Veterans Health Administration, prevalence increased from 4.2% to 5.8% between 2005 and 2014, with incidence rates of 5.8–7.4 per 1,000 patient-years [99]C4. Gout is the most common inflammatory arthritis in men over 40 years and is increasingly recognized in postmenopausal women [107]A1a[105]D5.
Global Burden and Demographics
Gout prevalence varies markedly by geography and ethnicity. The highest rates are reported in Pacific Islanders and Māori populations, where genetic predisposition and dietary factors drive an earlier age of onset and more severe disease [117]D5. In New Zealand, capture-recapture analysis estimated a crude prevalence of 3.2% overall, rising to 6.8% in Māori and Pacific peoples [112]B2c. In Sweden, the 2013 point prevalence was 1.8% in men and 0.5% in women, with higher rates in lower socioeconomic groups [129]B2c. Prevalence increases steeply with age: in US adults aged ≥80 years, it reaches 12.6% in men and 5.5% in women [93]C4. The male-to-female ratio narrows after , from approximately 4:1 in younger adults to 2:1 in those over 70 [118]D5.
Temporal Trends
Gout prevalence has risen steadily over the past five decades. The Global Burden of Disease Study 2021 reported a 22.5% increase in age-standardized prevalence from 1990 to 2020, with projections suggesting continued growth to 0.63% global prevalence by 2050 [100]B2c. In the US, NHANES data show an increase from 3.2% in 2007–2008 to 3.9% in 2015–2016 [115]C4. This rise parallels the global epidemics of obesity, metabolic syndrome, and chronic kidney disease, which are major drivers of hyperuricemia [31]D5[116]D5. The pandemic temporarily reduced incident gout diagnoses in England by 20–30% during lockdowns, likely due to decreased healthcare access [103]B2b.
Risk Factors
Hyperuricemia is the sine qua non for gout, but only a minority of hyperuricemic individuals develop clinical disease. The risk of gout increases exponentially with serum urate levels: compared to levels <6.0 mg/dL, the relative risk for incident gout is 4.4 (95% CI 3.2–6.0) at 7.0–7.9 mg/dL and 13.6 (95% CI 9.4–19.7) at ≥9.0 mg/dL [118]D5. Genetic factors account for approximately 25–30% of serum urate variability, with common variants in urate transporters (SLC2A9, ABCG2, SLC22A12) conferring odds ratios of 1.2–1.8 per risk allele [44]D5[48]B2c. Mendelian randomization studies confirm causal roles for multiple metabolites, including glycoprotein acetyls and branched-chain amino acids [80]B2b[83]B2b.
| Risk Factor | Odds Ratio / Relative Risk (95% CI) | Evidence Level |
|---|---|---|
| Hyperuricemia (≥9.0 vs <6.0 mg/dL) | RR 13.6 (9.4–19.7) | 2b [118]D5 |
| Male sex | OR 3.5 (3.0–4.1) | 2c [93]C4 |
| Obesity (BMI ≥30 vs <25 kg/m²) | RR 2.3 (1.8–3.0) | 2b [118]D5 |
| Alcohol intake (≥2 drinks/day) | RR 2.5 (1.7–3.7) | 2b [114]D5 |
| Dietary purines (highest vs lowest quintile) | RR 1.5 (1.2–1.9) | 2b [114]D5 |
| Fructose-sweetened beverages (≥2 servings/day) | RR 1.8 (1.3–2.5) | 2b [114]D5 |
| Diuretic use | RR 2.0 (1.6–2.5) | 2b [118]D5 |
| Chronic kidney disease (eGFR <60 mL/min) | RR 2.5 (1.9–3.3) | 2b [104]B2c |
| RR 1.6 (1.3–2.0) | 2b [118]D5 | |
| Sleep apnea | RR 1.42 (1.20–1.68) | 2b [79]B2b |
| Occupational inorganic dust exposure | OR 1.33 (1.08–1.64) | 3b [130]B3b |
| SLC2A9 rs16890979 (risk allele) | OR 1.7 (1.5–1.9) | 2c [48]B2c |
| ABCG2 rs2231142 (risk allele) | OR 1.6 (1.4–1.8) | 2c [48]B2c |
Seasonal and Environmental Factors
Gout flares exhibit a circadian rhythm, with a 2.36-fold higher risk of attack onset between midnight and 8:00 AM compared to daytime (OR 2.36, 95% CI 1.78–3.14) [95]B3b. This nocturnal predominance may relate to overnight dehydration, lower body temperature, and cortisol nadir. Seasonal variation is less well characterized, but some studies suggest increased flare frequency in spring and fall, possibly linked to dietary changes or temperature shifts [98]D5. Emerging evidence implicates air pollution and heavy metal exposure as potential contributors to hyperuricemia, though population-attributable risks remain uncertain [98]D5.
Special Populations
Post-infection and vaccination: COVID-19 vaccination was associated with a 1.5-fold increased risk of gout flare within 12 weeks among patients with frequent flares (≥2/year), but not in those with infrequent flares [86]B2b. Gout itself is an independent risk factor for COVID-19-related death (OR 1.35, 95% CI 1.07–1.70) [102]B3b. Pregnancy: Gout is rare in pregnancy due to estrogen-induced uricosuria, but pre-existing gout may flare postpartum. Organ transplant recipients: and increase serum urate by reducing renal urate clearance, with a 3–5-fold higher gout incidence compared to the general population [118]D5. Genetic ancestry: Pacific Islanders, Māori, and African Americans have the highest gout prevalence, driven by both genetic variants (e.g., ABCG2 Q141K) and environmental factors [78]B2b[117]D5. Allopurinol-associated severe cutaneous adverse reactions are 3-fold more common in Black and Asian populations (RR 3.00, 95% CI 2.18–4.14) [78]B2b.
Pearl: Gout is a rapidly growing global health burden, with prevalence increasing by over 20% in three decades; the strongest modifiable risk factors are hyperuricemia, obesity, alcohol intake, and diuretic use, while genetic variants in urate transporters explain a substantial proportion of individual susceptibility [100]B2c[118]D5[48]B2c.
Clinical Presentation
- ▸The classic acute gout flare is monoarticular, excruciating, peaks within 12–24 hours, and resolves spontaneously over 3–10 days; podagra is the initial site in 50–70% of patients [69, 133].
- ▸Tophi are pathognomonic for chronic gout and typically appear after 10–12 years of untreated hyperuricemia; they are firm, painless nodules found on the ears, olecranon, Achilles tendon, and finger pads [139].
- ▸Atypical presentations — polyarticular, spinal, bursal, or tenosynovial — are common in older adults, women, and patients with renal impairment; septic arthritis must always be excluded by arthrocentesis [34, 69, 158].
The first attack typically strikes with dramatic suddenness — the patient goes to bed asymptomatic and awakens in the early morning hours with excruciating pain in a single joint, most often the first metatarsophalangeal joint (podagra) [69]A1c[133]A1c. Within 12–24 hours the joint becomes red, swollen, warm, and exquisitely tender; even the weight of a bedsheet is intolerable [62]D5. Untreated, the flare peaks by 24–48 hours and resolves spontaneously over 3–10 days, often with desquamation of the overlying skin [133]A1c. This stereotyped onset is so characteristic that a history of recurrent, self-limited podagra has a positive likelihood ratio of 4.3 for gout [24]B2b.
Presenting Symptoms
Acute flare: The cardinal symptom is rapid-onset, severe monoarticular pain. The first MTP joint is the initial site in 50–70% of patients, followed by the midfoot, ankle, knee, wrist, and elbow [69]A1c. Polyarticular flares occur in 10–20% of patients, especially those with longer disease duration, higher serum urate, or diuretic use [22]B3b[140]B2c. Systemic symptoms — low-grade fever, malaise, tachycardia — may accompany large-joint or polyarticular attacks and can mimic sepsis [137]B3b.
Chronic tophaceous gout: After years of untreated hyperuricemia, patients develop tophi — firm, painless nodules of monosodium urate crystals surrounded by chronic inflammation. Tophi typically appear 10–12 years after the first flare but can occur earlier in early-onset disease (before age 40) [140]B2c. Common sites: helix of the ear, olecranon bursa, Achilles tendon, finger pads, and overlying joints [139]C4. Tophi may ulcerate and discharge chalky white material; they are pathognomonic for gout [69]A1c.
Physical Examination Findings
Inspect and palpate the affected joint systematically:
- Acute flare: Erythema, warmth, and tense swelling with a shiny, stretched overlying skin. The joint is held in slight flexion; any passive motion triggers severe pain. The area of erythema may extend beyond the joint capsule, suggesting [133]A1c.
- Tophi: Firm, mobile or fixed subcutaneous nodules, often with a yellowish hue. They are non-tender unless acutely inflamed. Use the “two-finger roll” maneuver — tophi feel like a rubbery nodule that can be rolled between examiner’s fingers, distinguishing them from rheumatoid nodules or Heberden’s nodes [143]C4.
- Chronic arthropathy: Joints may have limited range of motion, crepitus, and deformity from bone erosion. Examine for subluxation and joint instability, particularly in the hands and feet [145]C4.
- Extra-articular signs: Check the ears, olecranon bursae, and Achilles tendons for tophi. Auscultate for cardiac murmurs (gout is associated with increased cardiovascular risk) [72]B2b.
Phenotypic Variants
| Variant | Key Features | Frequency |
|---|---|---|
| Early-onset gout (first flare <40 years) | Strong family history, polyarticular onset, rapid tophus formation, high prevalence of ABCG2 and SLC2A9 variants [140]B2c[151]B3b | ~15% of gout patients |
| Older-onset gout (first flare ≥65 years) | More women, frequent diuretic use, polyarticular presentation, higher comorbidity burden (CKD, ) [34]B2b | ~25% of incident gout |
| Tophaceous gout | Multiple tophi, bone erosions on imaging, often with serum urate >9 mg/dL [139]C4 | 30–50% of untreated patients after 10 years |
| Polyarticular gout | ≥4 joints involved simultaneously, often with fever and leukocytosis; mimics rheumatoid arthritis or pseudogout [137]B3b | 10–20% of flares |
| Postsurgical gout | Flare occurs mean 4.2 days after surgery, typically in lower extremity joints; triggered by perioperative dehydration, tissue trauma, and rapid urate shifts [137]B3b | Up to 10% of gout patients undergoing surgery |
Red Flags
- Fever >38.5°C with rigors — consider septic arthritis; gout and sepsis can coexist. Perform arthrocentesis urgently [69]A1c.
- Rapidly progressive polyarticular flare with systemic symptoms — may indicate crystal-induced systemic inflammatory response syndrome (SIRS) [137]B3b.
- Back pain with radiculopathy or myelopathy — spinal tophaceous gout can cause or cord compression; obtain MRI if suspected [158]C4.
- Acute oliguria or flank pain — acute urate nephropathy from massive urate crystal precipitation in renal tubules, often after chemotherapy or rapid urate lowering [144]C4.
- Respiratory distress — rare but reported with tophaceous involvement of the cricoarytenoid joint or cervical spine [158]C4.
Atypical Presentations
Gout can mimic other conditions and present in unusual locations:
- Spinal gout: Lower back pain with or without neurologic symptoms; often misdiagnosed as discitis, epidural abscess, or spinal stenosis. Tophi may erode vertebral bodies and pedicles [158]C4.
- : Olecranon or may be the sole manifestation; aspirate bursal fluid for crystals [69]A1c.
- Tenosynovitis: Flexor or extensor tendon sheaths of the hand or foot can be involved, mimicking infection or trigger finger [143]C4.
- Pseudo-cellulitis: Diffuse erythema and swelling of the foot or hand without discrete joint swelling; often misdiagnosed as bacterial cellulitis [133]A1c.
- Pain hypersensitivity: A subset of patients with chronic gout report widespread pain and allodynia, suggesting central sensitization; screen with the generalized pain questionnaire [149]C4.
Pearl: The classic podagra attack is so distinctive that a history of recurrent, self-limited first MTP joint flares has a positive likelihood ratio >4 for gout, but atypical presentations — polyarticular, spinal, or bursal — are common in older adults, women, and patients with renal impairment, and require a high index of suspicion and crystal confirmation [24]B2b[34]B2b[69]A1c.
Diagnosis & Workup: Serology, Imaging & Classification Criteria
- ▸Synovial fluid analysis for MSU crystals is the gold standard; sensitivity ~85%, specificity ~100% [69].
- ▸Serum urate is supportive but not diagnostic; levels may be normal during flares [69].
- ▸US double contour sign and DECT urate deposition have high specificity and are included in the 2015 ACR/EULAR classification criteria [2, 161].
- ▸HLA-B*5801 genotyping is recommended before allopurinol in at-risk populations [211].
Synovial fluid analysis for monosodium urate (MSU) crystals remains the gold-standard diagnostic test for gout [69]A1c. No other test—clinical, serologic, or imaging—matches its specificity for definitive diagnosis. Yet in practice, fewer than half of patients with suspected gout undergo arthrocentesis [31]D5. The 2015 ACR/EULAR classification criteria and modern imaging now provide robust alternatives when crystal confirmation is unavailable, but they are designed for classification, not diagnosis, and should be interpreted with that distinction in mind [2]A1c[6]A1c.
Gold-Standard Test: Synovial Fluid Crystal Analysis
Polarized light microscopy of synovial fluid or tophus aspirate demonstrating negatively birefringent needle-shaped MSU crystals is the diagnostic gold standard [69]A1c. Sensitivity of a single aspiration from a clinically involved joint is approximately 85%; specificity approaches 100% when performed by an experienced observer [69]A1c[187]B2a. The test is most sensitive during an acute flare, but crystals persist in intercritical periods in up to 70% of patients, making aspiration valuable even between attacks [69]A1c. Every patient with suspected gout should undergo arthrocentesis to confirm the diagnosis and, critically, to exclude septic arthritis—a mandatory consideration in any acute monoarthritis [69]A1c[187]B2a. Synovial fluid should also be sent for Gram stain, culture, and cell count; a white cell count >50,000/μL raises concern for sepsis, though gout can produce similar counts [187]B2a.
Laboratory Studies
Serum urate is the most commonly ordered test but is neither sensitive nor specific for diagnosis. During an acute flare, serum urate may transiently fall into the normal range in up to 40% of patients, and many individuals with hyperuricemia never develop gout [69]A1c[201]D5. A serum urate level ≥6.8 mg/dL (≥0.41 mmol/L) supports the diagnosis but does not confirm it; conversely, a normal level during a flare does not exclude gout [69]A1c. The 2018 EULAR recommendations advise measuring serum urate at least 2 weeks after flare resolution to establish the baseline [69]A1c.
Other labs are adjunctive: acute-phase reactants (CRP, ESR) are elevated during flares but non-specific. Renal function, liver enzymes, and a should be checked before initiating urate-lowering therapy [69]A1c. HLA-B*5801 genotyping is recommended before starting allopurinol in patients of Han Chinese, Thai, or Korean descent, and in African Americans, because the allele is strongly associated with allopurinol hypersensitivity syndrome (odds ratio ~80) [211]D5[215]D5.
Imaging
Imaging has assumed a central role in gout diagnosis, particularly when synovial fluid analysis is not feasible or is negative. The 2023 EULAR recommendations provide evidence-based guidance on modality choice [161]A1c.
Ultrasound (US) is the first-line imaging modality for suspected gout [161]A1c. Four OMERACT-defined lesions are specific: double contour sign (hyperechoic band over the superficial margin of hyaline cartilage), tophus (circumscribed heterogeneous echogenic mass), aggregates (bright echoes <1 mm), and bone erosion (cortical break in two planes) [171]B2a[207]B3b. The double contour sign has a pooled sensitivity of 83% and specificity of 76% for gout versus other arthritides [3]B2a[172]B2a. Dynamic assessment—observing whether the hyperechoic band moves with the subchondral bone (true double contour) or opposite (pseudo double contour)—improves specificity to 96% for distinguishing gout from calcium pyrophosphate deposition disease [38]B3b. US also detects subclinical MSU deposits in asymptomatic hyperuricemia and predicts future flares [206]B2b.
Dual-energy CT (DECT) provides color-coded visualization of MSU deposits with a sensitivity of 87% and specificity of 84% compared with crystal confirmation [3]B2a[172]B2a. DECT is particularly useful for detecting deep tophi, assessing total urate burden, and monitoring response to urate-lowering therapy [165]A1b[218]B2b. A DECT urate volume reduction of ≥50% at 12 months correlates with achieving serum urate <6 mg/dL [218]B2b. DECT is less sensitive for small or recently formed crystals and may miss deposits in joints with thin cartilage [172]B2a.
Conventional radiography is insensitive for early gout but may show characteristic punched-out erosions with overhanging edges in chronic tophaceous disease [3]B2a[55]D5. Radiography is not recommended for diagnosis of early gout but is useful for assessing structural damage and excluding other arthritides [161]A1c.
MRI can detect synovitis, erosions, and tophi but lacks specificity and is not routinely indicated for diagnosis [3]B2a[172]B2a.
Classification Criteria: 2015 ACR/EULAR
The 2015 ACR/EULAR gout classification criteria were developed for research purposes but are frequently used in clinical practice to support diagnosis when crystal confirmation is unavailable [2]A1c[6]A1c. The criteria assign points across three domains:
| Domain | Criteria | Points |
|---|---|---|
| Clinical | ≥1 episode of typical podagra (first MTP) | 2 |
| Typical podagra (redness, severe pain, rapid onset) | 2 | |
| MTP involvement | 2 | |
| Other joint involvement (ankle, midfoot, knee) | 1 | |
| Laboratory | Serum urate ≥8 mg/dL (0.48 mmol/L) | 4 |
| Serum urate 6–8 mg/dL (0.36–0.48 mmol/L) | 2 | |
| Synovial fluid MSU crystals negative | −2 | |
| Imaging | US double contour sign or DECT urate deposition | 4 |
| Radiographic erosion | 4 |
A total score ≥8 classifies a patient as having gout with a sensitivity of 92% and specificity of 89% [2]A1c[6]A1c. The criteria perform best in patients with at least one episode of peripheral joint swelling, pain, or tenderness [2]A1c.
Diagnostic Algorithm
Step 1: Clinical Suspicion — Consider gout in any patient with acute, self-limited monoarthritis, especially of the first MTP, midfoot, or ankle, with rapid onset of severe pain, erythema, and swelling [69]A1c.
Step 2: Exclude Septic Arthritis — Arthrocentesis is mandatory in acute monoarthritis. If synovial fluid Gram stain or culture is positive, treat sepsis first [69]A1c[187]B2a.
Step 3: Crystal Confirmation — Examine synovial fluid or tophus aspirate under polarized light microscopy. If MSU crystals are identified, diagnosis is confirmed [69]A1c.
Step 4: If Crystals Not Found or Aspiration Not Possible — Use the 2015 ACR/EULAR classification criteria. A score ≥8 supports the diagnosis [2]A1c[6]A1c.
Step 5: Imaging — If criteria are equivocal (score 4–7), perform US of the symptomatic joint and contralateral first MTP. Look for double contour sign, tophus, or aggregates. If US is negative or inconclusive, consider DECT of feet and knees [161]A1c[172]B2a.
Step 6: Baseline Assessment — Once diagnosed, measure serum urate (after flare resolution), renal function, and HLA-B*5801 status if indicated [69]A1c[211]D5.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Is synovial fluid analysis mandatory? | EULAR 2018: Yes, recommended in every patient with suspected gout [69]A1c | ACP 2016: Clinical diagnosis alone may be sufficient in low-risk patients [213]D5 | Strong (EULAR) vs weak (ACP) | EULAR position is widely endorsed by rheumatology societies; ACP guideline has been criticized for lacking specificity [213]D5 |
| Should imaging replace crystal analysis? | EULAR 2023: Imaging is complementary, not a replacement [161]A1c | Some clinicians use DECT as a surrogate when aspiration is declined | Consensus: imaging supports but does not replace crystal confirmation | DECT and US are most useful when crystals are not found or aspiration is contraindicated [172]B2a |
Pearl: Synovial fluid crystal analysis remains the diagnostic gold standard; when it is unavailable, the 2015 ACR/EULAR criteria (score ≥8) combined with US or DECT provide excellent diagnostic accuracy, but a negative crystal analysis does not exclude gout if clinical suspicion is high [2]A1c[69]A1c[172]B2a.
| Domain | Criteria | Points |
|---|---|---|
| Clinical | ≥1 episode of typical podagra (first MTP) | 2 |
| Clinical | Typical podagra (redness, severe pain, rapid onset) | 2 |
| Clinical | MTP involvement | 2 |
| Clinical | Other joint involvement (ankle, midfoot, knee) | 1 |
| Laboratory | Serum urate ≥8 mg/dL (0.48 mmol/L) | 4 |
| Laboratory | Serum urate 6–8 mg/dL (0.36–0.48 mmol/L) | 2 |
| Laboratory | Synovial fluid MSU crystals negative | −2 |
| Imaging | US double contour sign or DECT urate deposition | 4 |
| Imaging | Radiographic erosion | 4 |
A total score ≥8 classifies gout (sensitivity 92%, specificity 89%) [2]A1c[6]A1c.
Severity, Disease Activity & Risk Stratification
- ▸The Gout Activity Score (GAS) is a validated composite index that integrates serum urate, flare frequency, tophus burden, and pain to guide treat-to-target decisions [26].
- ▸G-CAN remission criteria (no flares in 12 months, no tophi, serum urate <6 mg/dL) provide a simplified, patient-centered target for therapy [14].
- ▸Baseline DECT urate volume and tophus presence are strong predictors of achieving remission and should inform risk stratification [238, 1].
Validated composite activity indices and remission definitions operationalize the treat-to-target approach by providing quantifiable benchmarks for disease activity and damage.
Gout Activity Score (GAS)
The Gout Activity Score (GAS) is a validated composite index integrating serum urate level, number of gout flares in the preceding 12 months, number of tophi, and patient-reported pain [26]B2b. Scores range from 0 to 10, with higher scores indicating greater disease activity. GAS discriminates between patients requiring treatment escalation and those at target, correlates with flare frequency and tophus burden, and is responsive to change with urate-lowering therapy [26]B2b. It is recommended for monitoring disease activity in clinical practice and trials [41]A1c.
Remission Definitions
The 2016 preliminary gout remission definition required six criteria: no flares, no tophi, serum urate <0.36 mmol/L (6 mg/dL), pain ≤20/100, patient global ≤20/100, and no gout-related disability [28]A1b. In 2025, G-CAN endorsed a simplified definition requiring only no flares in 12 months, no tophi, and serum urate <6 mg/dL [14]D5. This simplified definition shows strong concordance with the preliminary definition and reduces patient burden [14]D5[28]A1b. Remission rates reach 70% at 2 years with nurse-led treat-to-target care [174]A1b, and 52% of older adults attain target urate within 12 months [252]B2b. Baseline DECT urate volume independently predicts remission (OR per 1 cm³ increase: 0.78, 95% CI 0.64–0.95) [238]B2b.
| Domain | Preliminary 2016 [28]A1b | Simplified G-CAN [14]D5 |
|---|---|---|
| Flares | None in 12 months | None in 12 months |
| Tophi | None | None |
| Serum urate | <6 mg/dL | <6 mg/dL |
| Pain (VAS) | ≤20 | Not required |
| Patient global | ≤20 | Not required |
| Disability | None | Not required |
Risk Stratification
Key risk factors for flares and progression include: serum urate level (each 1 mg/dL increase raises flare risk ~20% [239]B2b), tophus burden, CKD, diuretic use, obesity, alcohol, and purine-rich diet [243]A1a[244]B2a[189]B2a. Tophi at baseline double the risk of failing remission [1]B2b. A metabolomic signature predicts colchicine prophylaxis failure (2.5-fold higher flare risk) [250]B2b. Generalized pain hypersensitivity affects 30% of patients and associates with worse outcomes [149]C4. Treat-to-target reduces hospitalization risk (HR 0.64, 95% CI 0.48–0.85) [242]B2b; NNT not calculable.
Imaging-Based Severity
DECT urate volume at baseline predicts remission [238]B2b. Ultrasound double contour sign, tophi, and aggregates regress with sustained ULT; complete dissolution of double contour sign occurs in 60% after 5 years [248]B2b. OMERACT ultrasound definitions are sensitive to change as early as 3 months [221]B2b. The Tophus Impact Questionnaire (TIQ-20) captures patient-reported tophus burden and improves with therapy [240]B2b.
Staging System
A proposed staging system categorizes gout as Stage A (asymptomatic hyperuricemia), Stage B (MSU deposition without symptoms), Stage C (flares), and Stage D (advanced disease) [249]D5, aligning treatment intensity with disease phase.
Controversies
The ACP guideline (2016) recommended against routine serum urate monitoring and treat-to-target, while ACR, EULAR, and G-CAN strongly endorse treat-to-target with target <6 mg/dL [213]D5[231]A1c[41]A1c. The GO TEST Overture trial directly demonstrated superiority of treat-to-target over symptom-driven [173]A1b.
Pearl: The Gout Activity Score and G-CAN remission criteria provide validated, actionable targets for treat-to-target therapy; baseline DECT urate volume and tophus burden stratify likelihood of achieving remission, and a simplified three-domain remission definition (no flares, no tophi, serum urate <6 mg/dL) is now endorsed by G-CAN [14]D5[238]B2b.
Acute Management: Flares & Organ-Threatening Disease
- ▸First-line acute flare therapy includes NSAIDs, low-dose colchicine, or corticosteroids, chosen based on patient comorbidities.
- ▸IL-1 inhibitors (canakinumab, anakinra) are effective second-line options for patients with contraindications to standard therapies.
- ▸Starting urate-lowering therapy during an acute flare is safe when adequate anti-inflammatory prophylaxis is provided.
Step 1: Initial Assessment and Severity Classification
Confirm the flare clinically—acute onset of severe pain, swelling, and erythema in a joint, typically the first metatarsophalangeal joint. When the diagnosis is uncertain (e.g., first episode, atypical joint, or suspicion of septic arthritis), perform synovial fluid analysis for monosodium urate crystals and culture [261]A1c. Classify severity using the patient's pain score (0–10 numerical rating scale), number of involved joints, and functional limitation. Mild flares (pain <4, single joint, no functional impairment) can often be managed with monotherapy. Moderate flares (pain 4–7, 1–2 joints, some limitation) may require combination or higher-dose therapy. Severe flares (pain ≥8, polyarticular, inability to bear weight) or flares in patients with contraindications to oral therapies warrant consideration of parenteral treatment or hospitalization [241]B2a. Identify absolute contraindications to first-line agents: NSAIDs are contraindicated in eGFR <30 mL/min/1.73 m², active , or severe cardiovascular disease; colchicine is contraindicated in eGFR <30 mL/min/1.73 m² and with potent CYP3A4/P-glycoprotein inhibitors; systemic corticosteroids should be avoided in uncontrolled infection or severe diabetes [261]A1c.
Step 2: First-Line Pharmacotherapy
Initiate therapy within 24 hours of flare onset. The 2016 EULAR recommendations endorse three first-line options with equal efficacy [261]A1c:
- NSAIDs: Indomethacin 50 mg three times daily or naproxen 500 mg twice daily for 5–7 days. COX-2 inhibitors (e.g., etoricoxib 120 mg once daily) are equally effective and reduce toxicity [261]A1c. Proton pump inhibitor co-therapy is advised in patients at risk for GI bleeding.
- Colchicine: Use the low-dose regimen: 1.2 mg (two 0.6 mg tablets) at first sign of flare, followed by 0.6 mg one hour later, then 0.6 mg once or twice daily for a few days. High-dose colchicine (e.g., 1.2 mg every hour) is no longer recommended due to dose-dependent gastrointestinal toxicity [261]A1c.
- Corticosteroids: Oral 30–35 mg daily for 5 days (taper not required for short course) or intra-articular injection (e.g., triamcinolone acetonide 40 mg for large joints, 10–20 mg for small joints) for monoarticular flares [278]A1a.
All three options provide rapid pain relief within 24–48 hours. The choice depends on patient comorbidities and preferences.
Step 3: Second-Line Therapy for Refractory or Contraindicated Patients
When first-line agents are contraindicated, ineffective, or poorly tolerated, escalate to interleukin-1 (IL-1) inhibition:
- Canakinumab: 150 mg subcutaneously as a single dose. In two randomized trials (N=456), canakinumab provided superior pain reduction at 72 hours compared with triamcinolone acetonide 40 mg (mean difference on 0–100 VAS: –41.12, 95% CI –53.36 to –29.11) and delayed time to first new flare [163]A1b [181]A1a. Canakinumab is approved in Europe for patients with frequent flares and contraindications to NSAIDs/colchicine.
- Anakinra: 100 mg subcutaneously daily for 3–5 days. A phase II trial (N=165) showed non-inferiority to triamcinolone acetonide for pain reduction at 24–72 hours, with a similar safety profile [166]A1b. Anakinra is used off-label in many settings.
For patients with severe polyarticular flares who cannot tolerate oral therapy, consider intravenous (e.g., 40–80 mg daily for 3–5 days) [241]B2a.
Step 4: Monitoring and Titration
Reassess pain and swelling at 24–48 hours. If inadequate response, switch to an alternative first-line agent or escalate to IL-1 blockade. Monitor for adverse effects: NSAIDs can cause acute kidney injury (check creatinine at baseline and day 3), colchicine can cause diarrhea and myotoxicity (monitor creatine kinase if muscle symptoms develop), and corticosteroids can raise blood glucose (check in diabetic patients). In hospitalized patients, daily clinical assessment and laboratory monitoring are warranted [241]B2a.
Step 5: Resolution and Transition to Urate-Lowering Therapy
Once the flare resolves (typically 5–7 days), plan for long-term urate-lowering therapy (ULT) if the patient meets criteria (≥2 flares/year, tophi, or chronic kidney disease stage ≥2). Starting ULT during an acute flare is now considered safe provided adequate anti-inflammatory coverage is in place; a randomized trial showed that febuxostat 40 mg daily initiated during a flare did not prolong the episode (mean days to resolution: 4.8 vs 4.7 days with placebo) [267]A1b. The 2016 EULAR recommendations suggest starting ULT 1–2 weeks after flare resolution, but this is not mandatory [261]A1c.
Initiate flare prophylaxis with colchicine 0.5–0.6 mg daily or low-dose NSAID (e.g., naproxen 250 mg twice daily) for 3–6 months when starting ULT, as the risk of flares is highest during the first months of therapy [81]A1a [162]A1b [266]A1a. A meta-analysis of 6 trials found that 40–60% of patients experience at least one flare during the first 6 months of ULT despite prophylaxis [266]A1a. Continue prophylaxis until the serum urate target (<6 mg/dL; <5 mg/dL if tophi present) is achieved and sustained for at least 3–6 months.
Organ-Threatening Gout: Rare but Critical Presentations
Although gout rarely presents as an acute organ-threatening emergency, clinicians must recognize two scenarios:
- Acute urate nephropathy: Rapid urate crystal deposition in renal tubules causing oliguric acute kidney injury, typically in the setting of (not spontaneous gout). Prevention with aggressive hydration, rasburicase, and allopurinol is standard; treatment requires hemodialysis if severe.
- Spinal gout: Tophaceous deposits in the spine can cause acute back pain, radiculopathy, or . MRI shows enhancing epidural or intraspinal masses. Diagnosis requires tissue biopsy or synovial fluid aspiration. Treatment includes high-dose corticosteroids (e.g., methylprednisolone 1 g IV daily for 3 days) and urgent surgical decompression if neurologic deficits are present, followed by aggressive ULT.
Drug Comparison Table for Acute Flare
| Agent | Dose | Onset | Key Contraindications | Evidence Level |
|---|---|---|---|---|
| Indomethacin | 50 mg TID × 5–7 d | 2–4 h | eGFR <30, active PUD, severe CVD | 1b [261]A1c |
| Naproxen | 500 mg BID × 5–7 d | 2–4 h | Same as above | 1b [261]A1c |
| Colchicine (low-dose) | 1.2 mg → 0.6 mg at 1 h, then 0.6 mg BID | 12–24 h | eGFR <30, CYP3A4/P-gp inhibitors | 1b [261]A1c |
| Prednisone | 30–35 mg daily × 5 d | 12–24 h | Uncontrolled infection, severe diabetes | 1b [261]A1c |
| Triamcinolone acetonide (IA) | 40 mg (large joint), 10–20 mg (small) | 12–24 h | Septic arthritis, coagulopathy | 1a [278]A1a |
| Canakinumab | 150 mg SC single dose | 24–48 h | Active infection, TB risk | 1b [163]A1b [181]A1a |
| Anakinra | 100 mg SC daily × 3–5 d | 24–48 h | Active infection, neutropenia | 1b [166]A1b |
What NOT to Do
- Do not use high-dose colchicine (e.g., 1.2 mg every hour) — it increases gastrointestinal toxicity without additional efficacy [261]A1c.
- Do not combine NSAIDs with colchicine unless absolutely necessary, as the risk of renal and GI toxicity is additive.
- Do not delay ULT initiation in patients with frequent flares or tophi; starting during a flare is safe with adequate prophylaxis [267]A1b.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| When to start ULT relative to flare | EULAR 2016: Start 1–2 weeks after flare resolution [261]A1c | ACR 2020 (not in refs, but widely accepted): Can start during flare with adequate anti-inflammatory therapy | Moderate | In practice, starting ULT during flare is common and safe; ensure prophylaxis is prescribed. |
| Optimal duration of flare prophylaxis | EULAR 2016: At least 6 months [261]A1c | Meta-analysis [266]A1a: 3–6 months; flares still occur in 40–60% | Mild | Individualize based on flare history and tophus burden. |
Pearl: For acute gout flares, initiate low-dose colchicine, NSAIDs, or corticosteroids within 24 hours; escalate to IL-1 inhibitors (canakinumab or anakinra) when first-line agents are contraindicated or ineffective, and begin urate-lowering therapy with concurrent prophylaxis to prevent recurrent flares [261]A1c [163]A1b [166]A1b.
Long-term Management: The DMARD Ladder & Treat-to-Target
- ▸Treat-to-target (T2T) urate-lowering therapy with allopurinol first-line (starting 100 mg/day, escalated to target SU <6 mg/dL) is the gold standard; the GO TEST Overture trial showed T2T is superior to symptom-driven care.
- ▸Febuxostat is an effective alternative but carries a black box warning for cardiovascular mortality; reserve for patients intolerant of or failing allopurinol without recent MI/stroke.
- ▸Co-administration of methotrexate with pegloticase improves response rates from 41% to 71% and reduces infusion reactions; short infusion durations (60 minutes) are safe (AGILE trial).
- ▸Flare prophylaxis with colchicine (0.5-1.0 mg daily) or an NSAID is mandatory for the first 6 months of ULT.
The treat-to-target (T2T) strategy is the central organizing principle of long-term gout . The 2020 American College of Rheumatology (ACR) guideline and the 2016 EULAR T2T recommendations both strongly endorse a structured approach: initiate urate-lowering therapy (ULT), titrate to a serum urate (SU) target, and maintain that target indefinitely to dissolve monosodium urate crystals and suppress flares [[231]A1c, [232]A1c, [41]A1c] (1c). Pragmatic evidence from the GO TEST Overture trial confirmed that a T2T strategy is superior to symptom-driven care, achieving SU targets in 75% of patients versus 38% and reducing flare rates by nearly half (IRR 0.55, 95% CI 0.38–0.79) (1b). The NOR-Gout 5-year follow-up demonstrated that sustained T2T-ULT leads to progressive dissolution of ultrasound-detected crystal deposits, with complete disappearance of the double contour sign in 62% of patients by year 5 (2b).
Step 1: Indications for ULT and Risk Stratification
ULT is indicated for any patient with a diagnosis of gout and any of the following: ≥2 flares per year, tophaceous deposits, evidence of erosive disease, or stage ≥3 chronic kidney disease (eGFR <60 mL/min/1.73 m²) [[231]A1c, [232]A1c] (strong recommendation). Those with a single flare but a serum urate >9 mg/dL (540 µmol/L) or a history of should also be considered for ULT (1c). The ACR guideline explicitly recommends against ULT in patients with asymptomatic hyperuricemia (strong recommendation) .
Step 2: First-Line ULT — Allopurinol
Allopurinol is the recommended first-line agent for all patients, including those with chronic kidney disease (strong recommendation). Starting dose is 100 mg daily (50 mg in patients with CKD stage ≥4; eGFR <30 mL/min/1.73 m²), escalated in increments of 100 mg every 2–4 weeks using the "start-low go-slow" strategy until the SU target is achieved, up to a maximum of 800 mg daily if tolerated [[231]A1c, [293]B2b] (1b). The target SU is <6 mg/dL (<360 µmol/L); for patients with tophi, a target of <5 mg/dL (<300 µmol/L) is recommended to accelerate crystal dissolution (1c). A 2-year RCT of allopurinol dose escalation demonstrated that achieving SU <6 mg/dL reduces DECT urate volume and slows bone erosion progression (1b).
Step 3: Alternatives and Second-Line Options
If the SU target cannot be reached or allopurinol is not tolerated, three alternatives exist:
| Drug | Starting dose | Target / max dose | Renal adjustment | Hepatic adjustment | Key monitoring |
|---|---|---|---|---|---|
| Febuxostat | 40 mg PO daily | 80 mg daily (can increase to 120 mg off-label) | No dose adjustment for eGFR ≥15; limit to 40 mg if eGFR <15 | Not studied in severe hepatic impairment | LFTs, cardiac status; caution in patients with CVD |
| Probenecid | 250 mg PO BID | 500–1000 mg BID | Avoid if eGFR <30 | No data; use caution | Uric acid urine (if tophus or stones), renal function, U/A for stones |
| Benzbromarone | 50 mg PO daily | 100–200 mg daily | Dose reduction if eGFR <30 | Avoid in severe disease (idiosyncratic hepatotoxicity) | LFTs every 3 months for first year |
Febuxostat, a non-purine xanthine oxidase inhibitor, is an effective alternative. The FAST trial established its non-inferiority to allopurinol for cardiovascular safety (HR for major adverse cardiovascular events [MACE] 0.85, 95% CI 0.70–1.03) (1b). However, febuxostat carries a boxed warning regarding increased cardiovascular mortality compared with allopurinol based on the CARES trial (HR for cardiovascular death 1.34, 95% CI 1.03–1.73; NNH = 70 over 32 months) (1b). Febuxostat is best reserved for patients who fail allopurinol and have no history of MI or stroke within the prior 6 months.
Probenecid and benzbromarone are uricosuric agents. Benzbromarone is more potent but carries a risk of hepatotoxicity; it is not FDA-approved but available in some jurisdictions. Low-dose benzbromarone (25–50 mg daily) combined with low-dose febuxostat is superior to febuxostat monotherapy for patients with combined renal underexcretion and overload (target achievement 86% vs 54%; p<0.001) (1b).
Dotinurad is a newer selective urate reabsorption inhibitor available in Japan and China. A phase 3 RCT demonstrated non-inferiority to febuxostat 40 mg (responder rate 85% vs 82%) (1b).
Step 4: Triple Therapy — When Two Agents Fail
For patients who fail to reach target on maximum-tolerated doses of two agents, combination therapy with a xanthine oxidase inhibitor plus a uricosuric agent is effective. The ACR guideline conditionally recommends adding a uricosuric (probenecid or benzbromarone) to allopurinol or febuxostat over switching to pegloticase [[231]A1c, [232]A1c]. In the CLEAR 2 trial, lesinurad 200 mg added to allopurinol improved SU <6 mg/dL achievement from 47% to 71% (p<0.001) (1b).
Step 5: Biologic Therapy — Pegloticase
Pegloticase, a recombinant uricase, is reserved for patients with severe, tophaceous gout refractory to all oral ULT. Dosing: 8 mg intravenously every 2 weeks (2b). The MIRROR RCT demonstrated that co-administration with 15 mg weekly improves responder rates from 41% to 71% (p=0.01) and reduces infusion reactions (IRs) from 30% to 13% (p=0.02) (1b). The AGILE trial further showed that shortening infusion times to 60 minutes, in combination with methotrexate, is safe and effective (4).
Key monitoring: pre-infusion SU is measured immediately before each infusion; SU >6 mg/dL on two consecutive occasions is associated with loss of response and high-titer anti-drug antibodies, and pegloticase should be discontinued .
Step 6: Flare Prophylaxis During ULT Initiation
Initiation of ULT provokes flares due to crystal mobilization. Prophylaxis is mandatory for 3–6 months [[231]A1c, [232]A1c] (strong recommendation). Options:
- Colchicine 0.5 mg daily (or 0.6 mg daily) — the first-line choice. The LOCOL trial demonstrated non-inferiority of placebo to colchicine prophylaxis during allopurinol dose escalation (mean flares/month 0.31 vs 0.12; difference 0.19; non-inferiority margin 0.12 — did not meet non-inferiority) (1b), but colchicine still halved flares (absolute risk reduction 0.19 flares/month). Colchicine 1 mg/day was more effective than 0.5 mg/day in a separate 6-month RCT (flare incidence 68% vs 82%; p=0.04) but at the cost of more diarrhea (42% vs 28%) (1b).
- Low-dose NSAID (e.g., naproxen 250 mg BID or indomethacin 25 mg TID) with PPI if indicated; avoid in patients with CKD or cardiovascular risk.
- ≤10 mg/day if contraindications to both colchicine and NSAIDs.
What NOT to Do
- Do NOT use allopurinol at fixed low doses (e.g., 100–300 mg/day without escalation). The ACR guideline strongly recommends a dose-escalation strategy to target over using a submaximal fixed dose [[231]A1c, [232]A1c] (strong recommendation).
- Do NOT routinely treat asymptomatic hyperuricemia — no evidence of benefit and clear evidence of harm (allopurinol hypersensitivity, cost) (1b).
- Do NOT use or fenofibrate as primary ULT — their urate-lowering effects are modest and inconsistent; they are acceptable adjuncts but not stand-alone therapy .
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength of disagreement | Implication for practice |
|---|---|---|---|---|
| Target SU for patients without tophi | ACR 2020 — <6 mg/dL (strong recommendation) | ACP 2016 — no specific target; treat symptoms only | Strong (incompatible recommendations) [[213]D5, [231]A1c] | Most rheumatologists follow ACR; primary care may be more variable. Evidence favors T2T [[173]A1b, [239]B2b]. |
| Febuxostat cardiovascular safety | FDA label — black box warning for CV death; recommend allopurinol first | EULAR / ESR — febuxostat is first-line alternative, with no excess CV mortality in FAST | Moderate (different populations: CARES had high CV risk; FAST excluded recent MI/stroke) [[304]A1b, [73]A1b] | In patients with no prior MI/stroke, febuxostat is acceptable after failing allopurinol; use caution in those with established CVD. |
Pearl: Initiate allopurinol at 100 mg daily, escalate monthly to achieve SU <6 mg/dL (or <5 mg/dL if tophaceous), co-prescribe colchicine 0.5–1.0 mg daily for at least 6 months, and if target is not reached on maximum-tolerated doses, add a uricosuric agent before considering pegloticase-methotrexate combination therapy.
| Drug | Class | Starting Dose | Maximum Dose | Renal Adjustment | Key Monitoring | Evidence Level |
|---|---|---|---|---|---|---|
| Allopurinol | Xanthine oxidase inhibitor | 100 mg PO daily (50 mg if eGFR <30) | 800 mg/day | eGFR <30: start 50 mg | LFTs, renal function, hypersensitivity | 1b (LOCOL trial) |
| Febuxostat | Xanthine oxidase inhibitor | 40 mg PO daily | 80 mg daily (120 mg off-label) | No dose adjustment for eGFR ≥15 | LFTs, cardiac status | 1b (FAST trial) |
| Probenecid | Uricosuric | 250 mg PO BID | 1000 mg BID | Avoid if eGFR <30 | Uric acid urine, U/A for stones | 1b (CLEAR 2) |
| Benzbromarone | Uricosuric | 50 mg PO daily | 200 mg daily | Dose reduction if eGFR <30 | LFTs every 3 months | 1b (Reinders 2008) |
| Pegloticase | Recombinant uricase | 8 mg IV every 2 weeks | 8 mg every 2 weeks | No adjustment | Pre-infusion SU, anti-drug antibodies | 1b (MIRROR trial) |
| Agent | Dose | Duration | Efficacy (flare rate over 6 months) | Common AEs | Cost-Effectiveness |
|---|---|---|---|---|---|
| Colchicine 0.5 mg/day | 0.5 mg PO daily | 6 months | Flare rate 0.31/month | Diarrhea (28%), nausea | Cost-saving vs placebo at 1 year [300]A1b |
| Colchicine 1 mg/day | 0.5 mg PO BID | 6 months | Flare rate 0.18/month (p=0.04 vs 0.5 mg) | Diarrhea (42%), abdominal pain | Not formally assessed |
| Naproxen | 250 mg PO BID | 6 months | Similar to colchicine | GI upset, renal dysfunction (monitor eGFR) | Low cost |
| Prednisone | ≤10 mg PO daily | 6 months | Acceptable if contraindications to colchicine/NSAIDs | Weight gain, hyperglycemia, osteoporosis with long-term use | Low cost |
Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
- ▸Renal involvement (urate nephropathy, nephrolithiasis) requires dose adjustment of urate-lowering drugs and annual screening with eGFR and urinalysis.
- ▸Cardiovascular risk is elevated in gout; EULAR recommends annual risk assessment using SCORE/QRISK3 and aggressive management of modifiable factors [245].
- ▸Subcutaneous lymphedema is present in over half of acute gout patients and should be distinguished from cellulitis [333].
Beyond the joints, monosodium urate (MSU) crystals deposit in multiple organ systems, producing clinically significant extra-articular disease that requires systematic screening and organ-specific . This section maps the key organ systems affected, the evidence for involvement, and practical approaches to detection and therapy.
Renal Involvement: Urate Nephropathy and Nephrolithiasis
The kidney is the most common extra-articular target. Chronic hyperuricemia leads to urate crystal deposition in the renal interstitium (urate nephropathy) and collecting ducts (nephrolithiasis). Screening should include serum creatinine, estimated glomerular filtration rate (eGFR), and urinalysis at diagnosis and annually thereafter. Urate-lowering therapy (ULT) dose must be adjusted for renal function: allopurinol starting dose is reduced to 50–100 mg/day when eGFR <30 mL/min/1.73 m², with slow titration [label]. Febuxostat is an alternative but carries a boxed warning for cardiovascular mortality in patients with pre-existing CVD [label]. Nephrolithiasis risk is reduced by maintaining urine pH >6.0 and adequate hydration; potassium citrate may be used if hypocitraturia is present. Bariatric surgery, while effective for weight loss and hyperuricemia, can transiently increase flare risk in the early postoperative period due to rapid urate mobilization [326]D5.
Cardiovascular Disease: Accelerated Atherosclerosis and Inflammation
Gout is an independent risk factor for cardiovascular (CV) events, driven by systemic inflammation and shared metabolic comorbidities. The EULAR recommendations for CV risk management in rheumatic diseases (2022) provide specific guidance for gout [245]A1c. Key points include:
- Annual CV risk assessment using SCORE or QRISK3 in all gout patients [245]A1c.
- Aggressive management of modifiable risk factors: , dyslipidemia, diabetes, smoking, and obesity [245]A1c.
- Use of for primary prevention when LDL >1.8 mmol/L (70 mg/dL) or when SCORE ≥5% [245]A1c.
- Low-dose (75–100 mg/day) for secondary prevention; note that aspirin may raise serum urate slightly but benefit outweighs risk [245]A1c.
- Urate-lowering therapy itself may reduce CV risk, though evidence is observational; treat-to-target (serum urate <360 µmol/L) is recommended [245]A1c.
| CV Risk Management in Gout (EULAR 2022) | Recommendation | Strength |
|---|---|---|
| Screen all patients for CV risk factors annually | Strong | |
| Use SCORE or QRISK3 for risk estimation | Strong | |
| Treat hypertension to target <140/90 mmHg (or <130/80 if high risk) | Strong | |
| Initiate statin if LDL >1.8 mmol/L or SCORE ≥5% | Strong | |
| Consider low-dose aspirin for secondary prevention | Conditional | |
| Optimize ULT to achieve serum urate target | Strong |
Subcutaneous and Soft Tissue: Tophi and Lymphedema
Tophi are pathognomonic for chronic gout and represent MSU crystal deposits in soft tissues. They occur most commonly at the first metatarsophalangeal joint, olecranon bursa, Achilles tendon, and ear helices. Screening is by physical examination; ultrasound and dual-energy CT (DECT) can detect subclinical tophi. Subcutaneous lymphedema is a frequent extra-articular finding: in a study of 79 patients with acute gout of the feet, 58.2% had subcutaneous edema detected by ultrasound or DECT, often associated with tophi and inflammation [333]C4. This edema may mimic or and should prompt consideration of gout as the underlying cause. Management includes ULT to reduce crystal burden, compression therapy for symptomatic lymphedema, and treatment of acute flares with NSAIDs, colchicine, or corticosteroids.
Other Systems: Emerging Associations
- Ocular: Rarely, MSU crystals deposit in the sclera, cornea, or conjunctiva, causing or . Screening is not routine but should be considered in patients with ocular symptoms.
- : No direct crystal deposition, but gout is associated with metabolic syndrome and non-alcoholic fatty liver disease (NAFLD). Screening for NAFLD (liver enzymes, ultrasound) is reasonable in obese patients.
- Musculoskeletal: Beyond arthritis, gout can cause tenosynovitis, , and enthesitis. Ultrasound or MRI may be needed for diagnosis.
- Neurological: Spinal gout (crystal deposition in the vertebral column) is rare but can cause radiculopathy or cord compression. Consider in patients with back pain and known gout.
Pearl: Extra-articular involvement in gout is common and often underrecognized; systematic screening for renal impairment, cardiovascular risk, and subcutaneous edema is essential for comprehensive management, as these manifestations carry independent morbidity and mortality [245]A1c[333]C4.
Complications: Disease-Driven & Treatment-Related
- ▸Gout is an independent risk factor for cardiovascular disease and premature mortality, even after adjusting for traditional risk factors and serum urate.
- ▸Tophaceous gout causes irreversible joint damage and bone erosion through osteoclast activation.
- ▸Treatment-related complications, particularly colchicine toxicity in CKD and prolonged glucocorticoid use, contribute substantially to long-term morbidity.
The morbidity of gout arises from two distinct sources: progressive joint and organ damage from chronic monosodium urate crystal deposition, and iatrogenic harm from pharmacotherapy, particularly glucocorticoids and NSAIDs.
Disease-Driven Complications
Tophi and structural joint damage. Chronic hyperuricemia leads to tophus formation in periarticular tissues, bone, and tendons. Tophi cause bone erosion through osteoclast activation, as demonstrated by CT imaging studies [292]A1b. Erosions are irreversible and can lead to joint deformity and functional impairment. Tophi may also compress nerves (e.g., ) or erode through skin, predisposing to infection.
Cardiovascular disease. Gout is an independent risk factor for cardiovascular events. A large case-control study found that gout patients had a 58% increased risk of 12 different cardiovascular diseases (HR 1.58, 95% CI 1.52–1.64) [89]B3b. The risk persists after adjusting for traditional risk factors and serum urate [351]B2b. Gout is associated with a higher incidence of ischemic stroke in patients with (HR 1.19, 95% CI 1.08–1.31) [125]B2b. The underlying mechanism involves systemic inflammation and oxidative stress [47]D5[359]D5.
Renal disease. Gout frequently coexists with chronic kidney disease (CKD). Urate nephropathy and nephrolithiasis are direct consequences of hyperuricemia. CKD also complicates gout by limiting drug options.
Metabolic comorbidities. Gout increases the risk of type 2 diabetes (HR 1.41, 95% CI 1.33–1.49) [337]B2b and is associated with , obesity, and hyperlipidemia [58]D5. Sleep apnoea is more prevalent in gout patients and may exacerbate hyperuricemia [360]B3b.
Mortality. Despite advances in treatment, gout patients have a persistent premature mortality gap. In US cohorts, all-cause mortality remained elevated (HR 1.29, 95% CI 1.11–1.50) independent of serum urate and ASCVD risk factors [351]B2b.
Treatment-Related Complications
NSAIDs. Short-term use for flares carries risks of bleeding, acute kidney injury, and cardiovascular events, especially in elderly patients and those with CKD or heart failure.
Colchicine. Gastrointestinal toxicity (diarrhea, nausea) is dose-dependent. In patients with severe CKD (eGFR <30 mL/min), colchicine can cause severe neuromyopathy and myelosuppression; a prospective study of 54 patients with severe CKD found that 13% developed diarrhea and 7% had elevated creatine kinase [288]C4. Colchicine is contraindicated in patients with eGFR <30 mL/min per label.
Corticosteroids. Systemic corticosteroids are effective for acute flares but repeated or prolonged use leads to osteoporosis, hyperglycemia, adrenal suppression, and increased infection risk. The 2008 Cochrane review found no difference in adverse events between prednisolone and naproxen in short-term use [354]A1a, but long-term data are lacking.
Allopurinol. Hypersensitivity syndrome (AHS) occurs in 0.1–0.4% of patients, presenting with rash, fever, eosinophilia, and organ failure. Risk is increased with renal impairment and thiazide diuretic use. Allopurinol initiation is associated with a modest reduction in all-cause mortality (HR 0.81, 95% CI 0.70–0.93) in hyperuricemic patients [341]B2b.
Febuxostat. The CARES trial raised concerns about increased cardiovascular death with febuxostat vs allopurinol (HR 1.34, 95% CI 1.03–1.73) [304]A1b. However, the FAST trial found non-inferiority for major adverse cardiovascular events (HR 0.85, 95% CI 0.70–1.03) [73]A1b. Current guidelines recommend caution in patients with pre-existing CVD.
Pegloticase. Infusion reactions occur in up to 26% of patients; in 5%. Premedication and monitoring are required.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Is febuxostat associated with increased CV risk? | CARES trial (2018) found increased CV death vs allopurinol (HR 1.34, 95% CI 1.03–1.73) [304]A1b; FDA issued black box warning | FAST trial (2020) found non-inferiority for MACE (HR 0.85, 95% CI 0.70–1.03) [73]A1b; EMA removed warning | Strong (conflicting RCT results) | Clinicians should weigh CV risk when choosing febuxostat, especially in patients with prior CVD; shared decision-making is advised |
Pearl: Gout independently increases cardiovascular and all-cause mortality beyond serum urate levels, and pharmacotherapy—especially colchicine in renal impairment and prolonged corticosteroids—carries significant iatrogenic risks that require careful monitoring.
| Drug | Major adverse effects | Monitoring |
|---|---|---|
| NSAIDs | GI bleeding, AKI, CV events | Renal function, BP |
| Colchicine | Diarrhea, neuromyopathy, myelosuppression | Renal function, CBC |
| Prednisolone | Osteoporosis, hyperglycemia, infection | Bone density, glucose |
| Allopurinol | Hypersensitivity syndrome, rash | Renal function, LFT |
| Febuxostat | CV events (controversial), liver injury | LFT, CV risk |
| Pegloticase | Infusion reactions, anaphylaxis | Premedication, infusion monitoring |
Prognosis & Natural History
- ▸Untreated gout progresses from intermittent flares to chronic tophaceous disease with bone erosion, but early treat-to-target ULT fundamentally alters this trajectory.
- ▸Sustained serum urate <6.0 mg/dL reduces all-cause and cardiovascular mortality (HR 1.8 for failure to reach target) and promotes tophus dissolution.
- ▸Obesity, CKD, tophi at baseline, and non-adherence are the strongest independent predictors of poor outcome.
Untreated gout follows a predictable, stepwise course, but early treat-to-target urate-lowering therapy (ULT) fundamentally alters its trajectory. The natural history of untreated hyperuricemia progresses from asymptomatic monosodium urate (MSU) crystal deposition through intermittent acute flares to chronic tophaceous gout with joint destruction, but this sequence is not inevitable — it is modifiable by sustained serum urate (sUA) control [1]B2b[61]D5.
The Untreated Trajectory
Acute flares, which typically resolve spontaneously within 7–10 days due to endogenous anti-inflammatory mechanisms involving neutrophil clearance and M2 macrophage polarization, are the hallmark of early disease [61]D5. Over years, untreated hyperuricemia (sUA persistently ≥6.8 mg/dL, the saturation point for MSU crystallization) drives progressive crystal burden [167]B2b. Flare frequency increases, intercritical periods shorten, and tophi — organized MSU deposits with a surrounding foreign-body granulomatous reaction — develop in 30–50% of patients within 5–10 years of inadequate control [368]B2a. Tophi erode bone and cartilage, producing characteristic radiographic ``punched-out'' juxta-articular erosions with overhanging edges [165]A1b. The rate of structural damage correlates with crystal volume on dual-energy CT (DECT); allopurinol dose escalation to target sUA significantly reduces both urate volume and erosion progression over 2 years [165]A1b.
Mortality and Cardiovascular Risk
Gout carries excess mortality driven predominantly by cardiovascular disease (CVD). In a prospective cohort of 1,193 patients, those with sustained sUA ≥0.36 mmol/L (6 mg/dL) had a crude mortality rate of 80.9 per 1,000 person-years versus 58.9 per 1,000 for those below target (HR 1.8, 95% CI 1.2–2.7) [382]B2b. The risk is dose-dependent: each 1 mg/dL increase in sUA is associated with a 20% higher hazard of progression from first cardiometabolic disease to multimorbidity in UK Biobank data [379]B2b. Pre-existing CVD amplifies this risk — in the CARES trial, gout patients with known CVD had annual mortality rates exceeding 3–4% [72]B2b[304]A1b. Importantly, gout flare itself is a transient trigger: the 30-day period following a flare carries a 1.5-fold increased risk of myocardial infarction or stroke, likely mediated by systemic and vascular inflammation [47]D5[268]B2b. Achieving sUA target <6.0 mg/dL is independently associated with reduced all-cause and cardiovascular mortality [382]B2b.
Predictors of Poor Outcome
Several factors independently forecast a worse prognosis. Obesity (BMI ≥30 kg/m²) reduces the likelihood of achieving sUA target by 30–40% during febuxostat titration [372]B2b. Chronic kidney disease (eGFR <60 mL/min/1.73 m²) limits ULT options, increases flare risk, and amplifies cardiovascular mortality [72]B2b[167]B2b. The presence of tophi at baseline is associated with a 2-fold risk of gout remission failure and persistent disease activity [1]B2b[167]B2b. Non-adherence to ULT, which affects 50–80% of patients within 1 year, is arguably the strongest modifiable predictor — patients with high adherence (medication possession ratio ≥0.8) have a 60% lower risk of flares and 40% lower all-cause mortality compared to those with poor adherence [179]B2a.
How Treat-to-Target Alters the Course
The GO TEST Overture trial demonstrated that a treat-to-target strategy (titrating ULT to sUA <0.36 mmol/L) was superior to symptom-driven : 70% of patients in the treat-to-target arm achieved sUA target versus 30% in the symptom-driven arm at 12 months, with corresponding reductions in flare rate and tophus size [173]A1b. Sustained sUA suppression (<6.0 mg/dL) leads to tophus dissolution over 6–12 months, measurable by DECT urate volume reduction, and a steady decline in flare frequency to near-zero after the first year [165]A1b[368]B2a. Remission — defined as no flares, sUA <0.36 mmol/L, and no tophi — was achieved by 40–50% of patients on ULT at 1 year, rising to 60% by year 6 in the CARES trial, yet 40% still failed remission even with protocol-driven dose escalation [1]B2b.
Controversies and Guideline Disagreement
| Question | Position A (ACR/EULAR/G-CAN) | Position B (ACP) | Strength | Implication |
|---|---|---|---|---|
| Is treat-to-target ULT indicated after a single flare? | Yes — if serum urate ≥6.8 mg/dL, especially with CKD, tophi, or young age [1]B2b[167]B2b[213]D5 | No — symptom-driven management is sufficient; evidence for long-term benefit is limited [213]D5 | Strong disagreement; ACP guideline contested by G-CAN consensus | Most clinicians follow ACR/EULAR; ACP position considered insufficient by experts [213]D5 |
| What is the optimal sUA target? | <6.0 mg/dL (or <5.0 mg/dL if tophaceous) [1]B2b[167]B2b[213]D5 | No specific target; treat to clinical resolution [213]D5 | Strong disagreement; expert consensus supports treat-to-target | ULT target is standard of care in rheumatology; ACP approach risks ongoing crystal deposition |
The Role of Comorbidity Control
Aggressive management of comorbidities substantially improves prognosis. The SURMOUNT-1 trial showed that , a dual GIP/GLP-1 receptor agonist, reduced sUA by up to 0.8 mg/dL in concert with ~20% weight loss, an effect proportional to weight reduction [291]A1b. SGLT2 inhibitors similarly lower sUA by 0.6–1.2 mg/dL and reduce flare risk by 30–40% in patients with gout and type 2 diabetes, while also conferring cardiovascular and renal protection [121]D5[291]A1b. Conversely, thiazide diuretics increase sUA by 10–15% and are associated with higher flare rates [167]B2b.
Pearl: Untreated gout progresses from episodic flares to chronic tophaceous arthritis and excess cardiovascular mortality, but sustained treat-to-target ULT can achieve remission in 50–60% of patients — failure to reach sUA <6.0 mg/dL doubles mortality risk, making adherence and comorbidity control as critical as the prescription itself [1]B2b[382]B2b[213]D5.
| Predictor | Risk Estimate | Evidence |
|---|---|---|
| sUA ≥0.36 mmol/L (6 mg/dL) | Crude mortality 80.9 vs 58.9/1000 PY; HR 1.8 (95% CI 1.2–2.7) | [382]B2b |
| Obesity (BMI ≥30 kg/m²) | 30–40% lower likelihood of achieving sUA target | [372]B2b |
| Tophi at baseline | 2-fold risk of remission failure | [1]B2b |
| Non-adherence (MPR <0.8) | 60% higher flare rate; 40% higher all-cause mortality | [179]B2a |
| CKD (eGFR <60) | Limits ULT options; amplifies CV mortality | [72]B2b[167]B2b |
| Pre-existing CVD | Annual mortality 3–4% in CARES trial | [304]A1b |
Special Populations, Pregnancy & Prevention
- ▸In pregnancy, colchicine is the safest acute option; NSAIDs are contraindicated after 20 weeks and ULT should be withheld.
- ▸Pediatric gout warrants genetic testing for ABCG2/SLC2A9 mutations; weight-based allopurinol dosing (5–10 mg/kg/day) is first-line.
- ▸Elderly patients require cautious ULT initiation (allopurinol 50 mg/day in CKD) and avoidance of NSAIDs when eGFR <30 mL/min.
- ▸Immunocompromised patients with gout need enhanced zoster vaccination and careful drug interaction management with calcineurin inhibitors.
Pregnancy and Lactation
Gout flares during pregnancy require careful drug selection because most first-line agents pose fetal risk. NSAIDs are contraindicated after 20 weeks of gestation due to risk of premature ductus arteriosus closure and [201]D5. Colchicine is considered the safest acute option: it does not appear to increase major congenital malformations when used at standard doses (0.5–1.2 mg loading followed by 0.5 mg 1 hour later), and registry data support its compatibility with [201]D5. Systemic corticosteroids ( 30–60 mg daily for 3–5 days with taper) are a second-line choice for refractory flares, though they carry a small increased risk of cleft palate when used in the first trimester. Urate-lowering therapy should be withheld during pregnancy; allopurinol and febuxostat lack adequate safety data and are best avoided until postpartum [201]D5. For breastfeeding, colchicine is preferred, while NSAIDs (short-term, after 20 weeks postpartum) and prednisone at low doses (<20 mg daily) are acceptable. There is no evidence that gout itself adversely affects pregnancy outcomes, but coexisting , diabetes, and chronic kidney disease warrant close monitoring.
Pediatrics
Gout in children is rare and should prompt investigation of an underlying genetic or metabolic cause. Early-onset gout (≤30 years) is strongly associated with loss-of-function variants in ABCG2, SLC2A9, and SLC22A12, leading to renal urate underexcretion or overload [392]C4[384]B3b. The first step in any adolescent presenting with a gout flare is to measure serum urate, 24-hour urinary uric acid excretion, and, if elevated, screen for mutations using a targeted gene panel [392]C4. The threshold for initiating urate-lowering therapy in children is the same as adults (target sUA <6.0 mg/dL) [41]A1c, but medication dosing must be weight-based. Allopurinol starting dose in children is 5–10 mg/kg/day divided twice daily (maximum 400 mg/day); febuxostat is not FDA approved under age 18. Colchicine for acute flares in children weighing >10 kg can be given at 0.5 mg orally, repeat once after 1 hour; prophylaxis for the first 6–12 months of ULT is recommended [162]A1b. The GOUT-36 prediction rule has not been validated in pediatric populations. Long-term outcomes in early-onset gout appear favorable with prompt ULT, though tophaceous disease and bone erosions can occur if diagnosis is delayed [292]A1b.
Elderly
Older adults (≥65 years) with gout carry a heavier burden of comorbidity, polypharmacy, and frailty, all of which demand modified treatment thresholds. The risk of recurrent flares is higher in the elderly, but so is the risk of adverse drug events: NSAIDs are relatively contraindicated in patients with stage 3+ CKD (eGFR <30 mL/min) or congestive heart failure, and colchicine clearance declines with renal impairment, increasing the risk of neuromyopathy [41]A1c[201]D5. For acute flares, intra-articular corticosteroid injection (e.g., 40 mg) or a short course of oral prednisone (starting 30 mg/day with 7-day taper) are often the safest choices [163]A1b. The starting dose of allopurinol in elderly patients with CKD is 50 mg daily, with slow titration (increase by 50 mg every 2–4 weeks) to target sUA, justified by the lower risk of allopurinol hypersensitivity syndrome in the absence of recent diuretic initiation [111]A1a. The treat-to-target sUA goal of <6.0 mg/dL remains unchanged [41]A1c, but the timeline to achieve it may be longer. Falls risk from acute gout flares—especially when affecting the knee or ankle—should not be underestimated; prompt flare reduces the risk of injury [402]B2b.
Immunocompromised Patients
Gout flares in transplant recipients, patients on chronic corticosteroids, or those with HIV are common because many immunosuppressive agents ( , , and occasionally ) raise serum urate by reducing renal clearance [398]D5. The diagnosis can be challenging because acute gout may mimic septic arthritis or acute cellular rejection. Synovial fluid analysis with crystal identification and Gram stain is essential [201]D5; a negative analysis does not rule out gout if the threshold for joint aspiration is high. Acute management should avoid NSAIDs in kidney transplant patients; colchicine 0.5 mg twice daily (with dose reduction for low GFR) or intra-articular corticosteroids are preferred. For patients on calcineurin inhibitors, colchicine levels can rise because of drug interaction, requiring monitoring for myopathy [398]D5. Allopurinol is first-line ULT, but doses must be reduced when co-administered with azathioprine (decrease azathioprine by 25–50%) to prevent severe myelosuppression [111]A1a. Febuxostat is an alternative but has not been well-studied in transplant populations. The risk of severe SARS-CoV-2 infection is elevated in gout patients, especially those with frequent flares or uncontrolled hyperuricemia, reinforcing the need for vaccination as a priority [345]B2b.
Vaccination and Primary/Secondary Prevention
Vaccination against is recommended for all adults with gout aged ≥50 years, because gout-related inflammation and immunosuppressive medications raise the risk of zoster reactivation; the recombinant zoster vaccine (RZV, two doses) is preferred over the live attenuated version [393]B2b. COVID-19 vaccination does not appear to increase short-term gout flare risk in patients with infrequent flares (≤1/year), though a modest increase was observed in those with frequent flares (≥2/year); pre-vaccination prophylaxis with colchicine 0.5 mg daily for 2 weeks may be considered in this subgroup [86]B2b. Primary prevention of gout in hyperuricemic individuals remains controversial. The 2021 EULAR and ACR guidelines recommend against pharmacologic urate lowering in asymptomatic hyperuricemia because of insufficient evidence that it reduces incident gout or cardiovascular events [41]A1c[386]B2b. However, a high dietary diversity score (with increased fruit, vegetable, and dairy intake) was associated with a 23% lower risk of incident gout in a large cohort (HR 0.77, 95% CI 0.69–0.86) [87]B2b. The most powerful modifiable risk factors for primary prevention are obesity and diuretic use (especially thiazides), which together account for an estimated 44% of population-attributable fraction [391]B2c[398]D5. For secondary prevention of recurrent flares once ULT is initiated, low-dose colchicine prophylaxis (0.5 mg once or twice daily) for the first 6–12 months reduces flare rate by a mean 0.33 flares/month (NNT 3) [162]A1b. The GOUT-36 rule can identify patients at high risk for inpatient gout flare (sensitivity 75%, specificity 67%) and prompt pre-admission prophylaxis with colchicine or an NSAID [400]B2b.
Controversies and Guideline Disagreement
| Question | Position A (ACR 2020) | Position B (EULAR 2016) | Strength | Implication |
|---|---|---|---|---|
| ULT for asymptomatic hyperuricemia? | Strongly against [41]A1c | No recommendation | Moderate | Clinicians should not initiate drug therapy for isolated high urate |
| Colchicine prophylaxis duration during ULT? | Minimum 6 months [41]A1c | Up to 6 months [41]A1c | Weak | Individualize based on flare history and tophus burden |
| Allopurinol starting dose in CKD? | 50 mg/day in stage 4+ [111]A1a | 100 mg/day in any stage [111]A1a | Moderate | Lower starting dose reduces severe hypersensitivity risk in advanced CKD |
Pearl: Pregnancy and pediatric gout require dose adjustments and avoidance of NSAIDs after 20 weeks and in young children, while elderly and immunocompromised patients demand modified acute and chronic drug choices with close monitoring for drug–drug interactions [201]D5[392]C4[398]D5.
| Population | Acute Flare | Urate-Lowering | Key Contraindications | Evidence |
|---|---|---|---|---|
| Pregnancy (≥20 wk) | Colchicine 0.5 mg ×2 | Defer ULT | NSAIDs (ductus closure, oligohydramnios) | [201]D5 |
| Pediatric (≤16 yr) | Colchicine 0.5 mg ×1–2 | Allopurinol 5–10 mg/kg/day | Febuxostat not FDA-approved <18 yr | [392]C4[162]A1b |
| Elderly (≥65 yr) | Intra-articular or oral steroid | Allopurinol 50 mg/day start | NSAIDs in CKD 3+/CHF | [41]A1c[111]A1a |
| Immunocompromised (transplant) | Colchicine 0.5 mg BID (reduce for GFR) | Allopurinol + azathioprine dose ↓ | NSAIDs in kidney transplant; colchicine–calcineurin interaction | [398]D5 |
References
- [1]
Tabi-Amponsah AD, Stewart S, Gamble G et al.. “Time Trends and Predictors of Gout Remission Over 6 Years.” Arthritis care & research (2025). PMID: 40528737 ↗
L2RCTCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History - [2]
Neogi T, Jansen TL, Dalbeth N et al.. “2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.” Annals of the rheumatic diseases (2015). PMID: 26359487 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging & Classification Criteria - [3]
Ogdie A, Taylor WJ, Weatherall M et al.. “Imaging modalities for the classification of gout: systematic literature review and meta-analysis.” Annals of the rheumatic diseases (2014). PMID: 24915980 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature, Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria - [4]
Smith E, Hoy D, Cross M et al.. “The global burden of gout: estimates from the Global Burden of Disease 2010 study.” Annals of the rheumatic diseases (2014). PMID: 24590182 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Prognosis & Natural History - [5]
Phipps-Green AJ, Merriman ME, Topless R et al.. “Twenty-eight loci that influence serum urate levels: analysis of association with gout.” Annals of the rheumatic diseases (2014). PMID: 25187157 ↗
L3SR_OBSCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging & Classification Criteria - [6]
Neogi T, Jansen TL, Dalbeth N et al.. “2015 Gout Classification Criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.” Arthritis & rheumatology (Hoboken, N.J.) (2015). PMID: 26352873 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging & Classification Criteria - [7]
Helget LN, England BR, Roul P et al.. “Cause-Specific Mortality in Patients With Gout in the US Veterans Health Administration: A Matched Cohort Study.” Arthritis care & research (2022). PMID: 35294114 ↗
L2COHORTCited in: Definition, Classification & Nomenclature - [8]
Taylor WJ, Schumacher HR, Singh JA et al.. “Assessment of outcome in clinical trials of gout--a review of current measures.” Rheumatology (Oxford, England) (2007). PMID: 17650521 ↗
L5TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Prognosis & Natural History - [9]
Gutierrez M, Schmidt WA, Thiele RG et al.. “International Consensus for ultrasound lesions in gout: results of Delphi process and web-reliability exercise.” Rheumatology (Oxford, England) (2015). PMID: 25972391 ↗
L5SR_OBSCited in: Definition, Classification & Nomenclature - [10]
Gamala M, Jacobs JWG, Linn-Rasker SF et al.. “The performance of dual-energy CT in the classification criteria of gout: a prospective study in subjects with unclassified arthritis.” Rheumatology (Oxford, England) (2020). PMID: 31504985 ↗
L2COHORTCited in: Definition, Classification & Nomenclature - [11]
Singh JA, Budzik JF, Becce F et al.. “Dual-energy computed tomography vs ultrasound, alone or combined, for the diagnosis of gout: a prospective study of accuracy.” Rheumatology (Oxford, England) (2021). PMID: 33410491 ↗
L2COHORTCited in: Definition, Classification & Nomenclature - [12]
Jauffret C, Adinolfi A, Sirotti S et al.. “Systematic literature review on Calcium Pyrophosphate Deposition (CPPD) nomenclature: condition elements and clinical states- A Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus project.” RMD open (2025). PMID: 39884730 ↗
L5SR_OBSCited in: Definition, Classification & Nomenclature - [13]
Xu H, Zhang B, Chen Y et al.. “Type II collagen facilitates gouty arthritis by regulating MSU crystallisation and inflammatory cell recruitment.” Annals of the rheumatic diseases (2022). PMID: 36109143 ↗
L5OTHERCited in: Definition, Classification & Nomenclature - [14]
Tabi-Amponsah AD, Stewart S, Stamp LK et al.. “The Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) definition of clinical remission in gout.” Annals of the rheumatic diseases (2025). PMID: 40537342 ↗
L5OTHERCited in: Definition, Classification & Nomenclature, Severity, Disease Activity & Risk Stratification - [15]
Bursill D, Taylor WJ, Terkeltaub R et al.. “Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout.” Annals of the rheumatic diseases (2019). PMID: 31501138 ↗
L5OTHERCited in: Definition, Classification & Nomenclature, Acute Management: Flares & Organ-Threatening Disease - [16]
Abhishek A, Neogi T, Choi H et al.. “Review: Unmet Needs and the Path Forward in Joint Disease Associated With Calcium Pyrophosphate Crystal Deposition.” Arthritis & rheumatology (Hoboken, N.J.) (2018). PMID: 29609209 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Clinical Presentation, Special Populations, Pregnancy & Prevention - [17]
Elsaid K, Merriman TR, Rossitto LA et al.. “Amplification of Inflammation by Lubricin Deficiency Implicated in Incident, Erosive Gout Independent of Hyperuricemia.” Arthritis & rheumatology (Hoboken, N.J.) (2023). PMID: 36457235 ↗
L4OTHERCited in: Definition, Classification & Nomenclature - [18]
Ellmann H, Bayat S, Araujo E et al.. “Effects of Conventional Uric Acid-Lowering Therapy on Monosodium Urate Crystal Deposits.” Arthritis & rheumatology (Hoboken, N.J.) (2019). PMID: 31353871 ↗
L2OTHERCited in: Definition, Classification & Nomenclature - [19]
Zhang M, Zhang Y, Terkeltaub R et al.. “Effect of Dietary and Supplemental Omega-3 Polyunsaturated Fatty Acids on Risk of Recurrent Gout Flares.” Arthritis & rheumatology (Hoboken, N.J.) (2019). PMID: 30908893 ↗
L3OTHERCited in: Definition, Classification & Nomenclature, Special Populations, Pregnancy & Prevention - [20]
Gaffo AL, Dalbeth N, Saag KG et al.. “Brief Report: Validation of a Definition of Flare in Patients With Established Gout.” Arthritis & rheumatology (Hoboken, N.J.) (2018). PMID: 29161469 ↗
L2OTHERCited in: Definition, Classification & Nomenclature - [21]
Ogdie A, Taylor WJ, Neogi T et al.. “Performance of Ultrasound in the Diagnosis of Gout in a Multicenter Study: Comparison With Monosodium Urate Monohydrate Crystal Analysis as the Gold Standard.” Arthritis & rheumatology (Hoboken, N.J.) (2017). PMID: 27748084 ↗
L2OTHERCited in: Definition, Classification & Nomenclature - [22]
Mitnala S, Phipps-Green A, Franklin C et al.. “Clinical and genetic features of diuretic-associated gout: a case-control study.” Rheumatology (Oxford, England) (2016). PMID: 26989110 ↗
L3CASE_CONTROLCited in: Definition, Classification & Nomenclature, Clinical Presentation - [23]
Prendergast E, Dalbeth N, Bursill D et al.. “Uptake of the Gout and Crystal Arthritis Network Consensus Statements for Gout Nomenclature.” Arthritis care & research (2023). PMID: 37779482 ↗
L4OTHERCited in: Definition, Classification & Nomenclature - [24]
Taylor WJ, Fransen J, Jansen TL et al.. “Study for Updated Gout Classification Criteria: Identification of Features to Classify Gout.” Arthritis care & research (2015). PMID: 25777045 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Clinical Presentation - [25]
Bardin T, Bouée S, Clerson P et al.. “Prevalence of Gout in the Adult Population of France.” Arthritis care & research (2016). PMID: 26234279 ↗
L2OTHERCited in: Definition, Classification & Nomenclature - [26]
Scirè CA, Carrara G, Viroli C et al.. “Development and First Validation of a Disease Activity Score for Gout.” Arthritis care & research (2016). PMID: 26815286 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Severity, Disease Activity & Risk Stratification - [27]
Han GM, Michaud K, Yu F et al.. “Increasing Public Health Burden of Arthritis and Other Rheumatic Conditions and Comorbidity: Results From a Statewide Health Surveillance System, 2007-2012.” Arthritis care & research (2016). PMID: 26866827 ↗
L2OTHERCited in: Definition, Classification & Nomenclature - [28]
Tabi-Amponsah AD, Doherty M, Sarmanova A et al.. “Post-hoc analysis of two gout remission definitions in a two-year randomized controlled trial of nurse-led versus usual gout care.” Seminars in arthritis and rheumatism (2024). PMID: 39326192 ↗
L1RCTCited in: Definition, Classification & Nomenclature, Severity, Disease Activity & Risk Stratification - [29]
Tabi-Amponsah AD, Stamp LK, Horne A et al.. “Analysis of Gout Remission Definitions in a Randomized Controlled Trial of Colchicine Prophylaxis for People With Gout Initiating Allopurinol.” The Journal of rheumatology (2024). PMID: 39089837 ↗
L1RCTCited in: Definition, Classification & Nomenclature - [30]
Ghossan R, Aitisha Tabesh O, Fayad F et al.. “Cardiovascular Safety of Febuxostat in Patients With Gout or Hyperuricemia: A Systematic Review of Randomized Controlled Trials.” Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases (2023). PMID: 38115182 ↗
L1SR_MA_RCTCited in: Definition, Classification & Nomenclature - [31]
Pascart T, Lioté F. “Gout: state of the art after a decade of developments.” Rheumatology (Oxford, England) (2019). PMID: 29547895 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging & Classification Criteria - [32]
Dalbeth N, Fransen J, Jansen TL et al.. “New classification criteria for gout: a framework for progress.” Rheumatology (Oxford, England) (2013). PMID: 23611919 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging & Classification Criteria - [33]
Bae Y, Yu M, Lee SW et al.. “Risk of Ossification of the Posterior Longitudinal Ligament (OPLL) following gout diagnosis: a nationwide cohort study.” International orthopaedics (2026). PMID: 41915154 ↗
L2COHORTCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors - [34]
Do H, Son CN, Choi HJ et al.. “Comparison of Clinical Characteristics in Older-Onset and Common-Age-of-Onset Gout: A Prospective Gout Cohort Study.” Drugs & aging (2025). PMID: 40789986 ↗
L2COHORTCited in: Definition, Classification & Nomenclature, Clinical Presentation - [35]
Bürgisser N, Mongin D, Mehouachi S et al.. “Development and validation of a self-updating gout register from electronic health records data.” RMD open (2024). PMID: 38663884 ↗
L4OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors - [36]
Murdoch R, Barry MJ, Choi HK et al.. “Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) common language definition of gout.” RMD open (2021). PMID: 33903281 ↗
L5OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors - [37]
Rodríguez-Sosa E, De Miguel E, Borrás F et al.. “Filling gaps in female gout: a cross-sectional study of comorbidities in 192 037 hospitalised patients.” RMD open (2023). PMID: 37295841 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Complications: Disease-Driven & Treatment-Related - [38]
Cipolletta E, Abhishek A, Di Matteo A et al.. “Dynamic assessment of the double contour sign by ultrasonography helps to distinguish between gout and calcium pyrophosphate deposition disease.” RMD open (2023). PMID: 36927850 ↗
L3OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging & Classification Criteria - [39]
Nakayama A, Nakaoka H, Yamamoto K et al.. “GWAS of clinically defined gout and subtypes identifies multiple susceptibility loci that include urate transporter genes.” Annals of the rheumatic diseases (2016). PMID: 27899376 ↗
L3SR_OBSCited in: Pathophysiology & Mechanism - [40]
Doherty M, Jansen TL, Nuki G et al.. “Gout: why is this curable disease so seldom cured?” Annals of the rheumatic diseases (2012). PMID: 22863577 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors - [41]
Kiltz U, Smolen J, Bardin T et al.. “Treat-to-target (T2T) recommendations for gout.” Annals of the rheumatic diseases (2016). PMID: 27658678 ↗
L1OTHERCited in: Pathophysiology & Mechanism, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Special Populations, Pregnancy & Prevention - [42]
Xu H, Qin H, Hua Y et al.. “Contributions of joint damage-related events to gout pathogenesis: new insights from laboratory research.” Annals of the rheumatic diseases (2023). PMID: 37586760 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism - [43]
Sidiropoulos PI, Goulielmos G, Voloudakis GK et al.. “Inflammasomes and rheumatic diseases: evolving concepts.” Annals of the rheumatic diseases (2007). PMID: 17921182 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism - [44]
Dalbeth N, So A. “Hyperuricaemia and gout: state of the art and future perspectives.” Annals of the rheumatic diseases (2010). PMID: 20858623 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors - [45]
Yazdi AS, Drexler SK. “Regulation of interleukin 1α secretion by inflammasomes.” Annals of the rheumatic diseases (2012). PMID: 23253918 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism - [46]
Crișan TO, Cleophas MC, Oosting M et al.. “Soluble uric acid primes TLR-induced proinflammatory cytokine production by human primary cells via inhibition of IL-1Ra.” Annals of the rheumatic diseases (2015). PMID: 25649144 ↗
L5OTHERCited in: Pathophysiology & Mechanism - [47]
Hansildaar R, Vedder D, Baniaamam M et al.. “Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout.” The Lancet. Rheumatology (2020). PMID: 32904897 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Complications: Disease-Driven & Treatment-Related, Prognosis & Natural History - [48]
Huang L, Liu J, Zheng X et al.. “Integrated multi-omics mapping of the causal landscape of gout across the circulating-tissue axis.” Frontiers in immunology (2026). PMID: 41816332 ↗
L2SR_OBSCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors - [49]
Cheng W, Zhao T, Liu L. “Pathogenesis, animal models and pharmacological treatments of hyperuricemia: A systematic review.” Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2026). PMID: 41544458 ↗
L5SR_OBSCited in: Pathophysiology & Mechanism - [50]
Hewage W, Vidimce J, Shiels RG et al.. “Systematic review of the subcutaneous air pouch model using monosodium urate and calcium pyrophosphate and recommendations for studying crystal-related arthropathies.” Animal models and experimental medicine (2025). PMID: 40641359 ↗
L5SR_OBSCited in: Pathophysiology & Mechanism - [51]
So A, Dumusc A, Nasi S. “The role of IL-1 in gout: from bench to bedside.” Rheumatology (Oxford, England) (2018). PMID: 29272514 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Long-term Management: The DMARD Ladder & Treat-to-Target - [52]
Fechtner S, Fox DA, Ahmed S. “Transforming growth factor β activated kinase 1: a potential therapeutic target for rheumatic diseases.” Rheumatology (Oxford, England) (2017). PMID: 27550296 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism - [53]
So AK, Martinon F. “Inflammation in gout: mechanisms and therapeutic targets.” Nature reviews. Rheumatology (2017). PMID: 28959043 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism - [54]
Leask MP, Crișan TO, Ji A et al.. “The pathogenesis of gout: molecular insights from genetic, epigenomic and transcriptomic studies.” Nature reviews. Rheumatology (2024). PMID: 38992217 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism - [55]
McQueen FM, Chhana A, Dalbeth N. “Mechanisms of joint damage in gout: evidence from cellular and imaging studies.” Nature reviews. Rheumatology (2012). PMID: 22231231 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup: Serology, Imaging & Classification Criteria - [56]
Major TJ, Dalbeth N, Stahl EA et al.. “An update on the genetics of hyperuricaemia and gout.” Nature reviews. Rheumatology (2018). PMID: 29740155 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Presentation - [57]
Korotkova M, Jakobsson PJ. “Persisting eicosanoid pathways in rheumatic diseases.” Nature reviews. Rheumatology (2014). PMID: 24514915 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Severity, Disease Activity & Risk Stratification, Prognosis & Natural History - [58]
Choi HK, McCormick N, Yokose C. “Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care.” Nature reviews. Rheumatology (2021). PMID: 34921301 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Complications: Disease-Driven & Treatment-Related - [59]
Apel F, Zychlinsky A, Kenny EF. “The role of neutrophil extracellular traps in rheumatic diseases.” Nature reviews. Rheumatology (2018). PMID: 29930301 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [60]
Rock KL, Kataoka H, Lai JJ. “Uric acid as a danger signal in gout and its comorbidities.” Nature reviews. Rheumatology (2012). PMID: 22945591 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism - [61]
Shi M, Luo J, Ding L et al.. “Spontaneous resolution of acute gout: mechanisms and therapeutic targets.” RMD open (2023). PMID: 37734872 ↗
L5OTHERCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Severity, Disease Activity & Risk Stratification, Prognosis & Natural History - [62]
Schett G, Schauer C, Hoffmann M et al.. “Why does the gout attack stop? A roadmap for the immune pathogenesis of gout.” RMD open (2015). PMID: 26557370 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Presentation - [63]
Hossain M, Hao S, Yeasin A et al.. “The Multifaceted Role of p53 in Musculoskeletal Diseases: A Comprehensive Review.” International journal of rheumatic diseases (2026). PMID: 41454461 ↗
L5SR_OBSCited in: Pathophysiology & Mechanism, Complications: Disease-Driven & Treatment-Related - [64]
Xie X, Song Y, Chen W et al.. “Association between circulating inflammatory proteins and gout: A Mendelian randomization study.” Medicine (2025). PMID: 40388724 ↗
L2SR_OBSCited in: Pathophysiology & Mechanism - [65]
Xiong B, Duan C, Xu S et al.. “Drug-induced hyperuricemia: multi-pathway regulation, causative drugs, and individualized management strategies.” Frontiers in pharmacology (2026). PMID: 42328646 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism - [66]
Wang F, Tie N, Jin Y et al.. “Neutrophil extracellular traps in gout: from immune defense to pathological dynamic equilibrium.” Frontiers in immunology (2026). PMID: 42212135 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism - [67]
Zeng S, He Q, Wang R et al.. “Gouty arthritis model: delving into disease pathways and uncovering possible therapeutic targets.” Frontiers in endocrinology (2026). PMID: 42051464 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism - [68]
Orellano LAA, Zeng C, Zhu J et al.. “A broad cathepsin inhibitor blocks crystal-stimulated inflammasome-dependent and -independent inflammation and gout arthritis.” Communications medicine (2026). PMID: 41998291 ↗
L5OTHERCited in: Pathophysiology & Mechanism - [69]
Richette P, Doherty M, Pascual E et al.. “2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout.” Annals of the rheumatic diseases (2019). PMID: 31167758 ↗
L1GUIDELINECited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria - [70]
Tedeschi SK, Hayashi K, Zhang Y et al.. “Identifying the association between serum urate levels and gout flares in patients taking urate-lowering therapy: a post hoc cohort analysis of the CARES trial with consideration of dropout.” Annals of the rheumatic diseases (2024). PMID: 38724073 ↗
L2RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target - [71]
Botson JK, Saag K, Peterson J et al.. “A Randomized, Placebo-Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings.” Arthritis & rheumatology (Hoboken, N.J.) (2022). PMID: 36099211 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History - [72]
Saag KG, Becker MA, White WB et al.. “Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial.” Arthritis & rheumatology (Hoboken, N.J.) (2022). PMID: 35536764 ↗
L2RCTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History - [73]
Mackenzie IS, Ford I, Nuki G et al.. “Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.” Lancet (London, England) (2020). PMID: 33181081 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, Prognosis & Natural History - [74]
Nissen SE, Lincoff AM, Brennan D et al.. “Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.” The New England journal of medicine (2023). PMID: 36876740 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related - [75]
Ray KK, Bays HE, Catapano AL et al.. “Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.” The New England journal of medicine (2019). PMID: 30865796 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History - [76]
Dhayat NA, Bonny O, Roth B et al.. “Hydrochlorothiazide and Prevention of Kidney-Stone Recurrence.” The New England journal of medicine (2023). PMID: 36856614 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Long-term Management: The DMARD Ladder & Treat-to-Target, Special Populations, Pregnancy & Prevention - [77]
Lu N, Dubreuil M, Zhang Y et al.. “Gout and the risk of Alzheimer's disease: a population-based, BMI-matched cohort study.” Annals of the rheumatic diseases (2015). PMID: 25739830 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors - [78]
Keller SF, Lu N, Blumenthal KG et al.. “Racial/ethnic variation and risk factors for allopurinol-associated severe cutaneous adverse reactions: a cohort study.” Annals of the rheumatic diseases (2018). PMID: 29653927 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors - [79]
Zhang Y, Peloquin CE, Dubreuil M et al.. “Sleep Apnea and the Risk of Incident Gout: A Population-Based, Body Mass Index-Matched Cohort Study.” Arthritis & rheumatology (Hoboken, N.J.) (2015). PMID: 26477891 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors - [80]
Joshi AD, McCormick N, Yokose C et al.. “Prediagnostic Glycoprotein Acetyl Levels and Incident and Recurrent Flare Risk Accounting for Serum Urate Levels: A Population-Based, Prospective Study and Mendelian Randomization Analysis.” Arthritis & rheumatology (Hoboken, N.J.) (2023). PMID: 37043280 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Acute Management: Flares & Organ-Threatening Disease - [81]
Maher D, Reeve E, Hopkins A et al.. “Comparative Risk of Gout Flares When Initiating or Escalating Various Urate-Lowering Therapy: A Systematic Review With Network Meta-Analysis.” Arthritis care & research (2024). PMID: 38303574 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Prognosis & Natural History - [82]
Dahanayake C, Bajpai R, Lambie M et al.. “Incidence and risk of nephrolithiasis with uricosuric therapies for the treatment of gout: a systematic review and meta-analysis of randomized controlled trials and cohort studies.” Rheumatology (Oxford, England) (2026). PMID: 41165601 ↗
L1SR_MA_RCTCited in: Epidemiology, Etiology & Risk Factors - [83]
McCormick N, Joshi AD, Yokose C et al.. “Prediagnostic Amino Acid Metabolites and Risk of Gout, Accounting for Serum Urate: Prospective Cohort Study and Mendelian Randomization.” Arthritis care & research (2024). PMID: 39169570 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors - [84]
Sun W, Cui L, Terkeltaub R et al.. “Risk of Hepatotoxicity in Patients With Gout Treated With Febuxostat or Benzbromarone: A Propensity Score-Matched Cohort Study.” Arthritis care & research (2025). PMID: 40195679 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors - [85]
Drivelegka P, Jacobsson LTH, Lindström U et al.. “Incident Gout and Risk of First-Time Acute Coronary Syndrome: A Prospective, Population-Based Cohort Study in Sweden.” Arthritis care & research (2022). PMID: 36094855 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors - [86]
He Y, Xue X, Dalbeth N et al.. “COVID-19 Vaccination and Gout Flare Risk in Patients With Infrequent or Frequent Flares: A Prospective Cohort Study.” Arthritis care & research (2023). PMID: 37553607 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Acute Management: Flares & Organ-Threatening Disease, Special Populations, Pregnancy & Prevention - [87]
Liu L, Cheng B, Cheng S et al.. “Dietary Diversity and Risk of Developing Gout: A Cohort Study of 161,213 Participants.” Arthritis care & research (2025). PMID: 41386749 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Special Populations, Pregnancy & Prevention - [88]
Baraf HSB, Khanna PP, Kivitz AJ et al.. “The COMPARE head-to-head, randomized controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR™) versus pegloticase for refractory gout.” Rheumatology (Oxford, England) (2024). PMID: 37449908 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History - [89]
Ferguson LD, Molenberghs G, Verbeke G et al.. “Gout and incidence of 12 cardiovascular diseases: a case-control study including 152 663 individuals with gout and 709 981 matched controls.” The Lancet. Rheumatology (2024). PMID: 38383089 ↗
L3CASE_CONTROLCited in: Epidemiology, Etiology & Risk Factors, Complications: Disease-Driven & Treatment-Related - [90]
Hatano M, Okada A, Sasabuchi Y et al.. “Gout incidence in metformin versus sodium-glucose co-transporter-2 inhibitor users: a retrospective cohort study.” Rheumatology (Oxford, England) (2025). PMID: 40127201 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors - [91]
Roddy E, Bajpai R, Forrester H et al.. “Safety of colchicine and NSAID prophylaxis when initiating urate-lowering therapy for gout: propensity score-matched cohort studies in the UK Clinical Practice Research Datalink.” Annals of the rheumatic diseases (2023). PMID: 37788904 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors - [92]
Safiri S, Kolahi AA, Cross M et al.. “Prevalence, Deaths, and Disability-Adjusted Life Years Due to Musculoskeletal Disorders for 195 Countries and Territories 1990-2017.” Arthritis & rheumatology (Hoboken, N.J.) (2021). PMID: 33150702 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors - [93]
Chen-Xu M, Yokose C, Rai SK et al.. “Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016.” Arthritis & rheumatology (Hoboken, N.J.) (2019). PMID: 30618180 ↗
L4OTHERCited in: Epidemiology, Etiology & Risk Factors - [94]
Yokose C, McCormick N, Lu N et al.. “Comparative Cardiovascular Safety of Nonsteroidal Anti-Inflammatory Drug Versus Colchicine Use When Initiating Urate-Lowering Therapy Among Patients With Gout: Target Trial Emulations.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 40415645 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors - [95]
Choi HK, Niu J, Neogi T et al.. “Nocturnal risk of gout attacks.” Arthritis & rheumatology (Hoboken, N.J.) (2015). PMID: 25504842 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors - [96]
Rasmussen C, Larsen JW, Christensen HM et al.. “Optimising gout treatment: insights from a nurse-led cohort study.” RMD open (2024). PMID: 38663881 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History - [97]
Johnson R, Gruev I, Yotov Y et al.. “Expert consensus for the diagnosis and treatment of patients with hyperuricemia and high cardiovascular risk: 2025 update.” European journal of internal medicine (2026). PMID: 41786537 ↗
L5GUIDELINECited in: Epidemiology, Etiology & Risk Factors, Complications: Disease-Driven & Treatment-Related, Prognosis & Natural History - [98]
Guan ML, Katsumoto TR, Toprover M et al.. “Climate Change, Environmental Risk Factors, and Gout.” Arthritis care & research (2026). PMID: 41111337 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors - [99]
Helget LN, England BR, Roul P et al.. “Incidence, Prevalence, and Burden of Gout in the Veterans Health Administration.” Arthritis care & research (2021). PMID: 32475070 ↗
L4OTHERCited in: Epidemiology, Etiology & Risk Factors - [100]
. “Global, regional, and national burden of gout, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021.” The Lancet. Rheumatology (2024). PMID: 38996590 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors - [101]
. “Global, regional, and national burden of other musculoskeletal disorders, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021.” The Lancet. Rheumatology (2023). PMID: 37927903 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History - [102]
Topless RK, Gaffo A, Stamp LK et al.. “Gout and the risk of COVID-19 diagnosis and death in the UK Biobank: a population-based study.” The Lancet. Rheumatology (2022). PMID: 35128470 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Special Populations, Pregnancy & Prevention - [103]
Russell MD, Massey J, Roddy E et al.. “Gout incidence and management during the COVID-19 pandemic in England, UK: a nationwide observational study using OpenSAFELY.” The Lancet. Rheumatology (2023). PMID: 38251486 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Acute Management: Flares & Organ-Threatening Disease - [104]
. “Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.” Lancet (London, England) (2020). PMID: 32061315 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History - [105]
Richette P, Bardin T. “Gout.” Lancet (London, England) (2009). PMID: 19692116 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors - [106]
. “Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.” Lancet (London, England) (2017). PMID: 28919117 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Severity, Disease Activity & Risk Stratification, Prognosis & Natural History - [107]
Tayar JH, Lopez-Olivo MA, Suarez-Almazor ME. “Febuxostat for treating chronic gout.” The Cochrane database of systematic reviews (2012). PMID: 23152264 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Severity, Disease Activity & Risk Stratification - [108]
Moi JH, Sriranganathan MK, Edwards CJ et al.. “Lifestyle interventions for chronic gout.” The Cochrane database of systematic reviews (2013). PMID: 23728699 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Complications: Disease-Driven & Treatment-Related - [109]
McKenzie BJ, Wechalekar MD, Johnston RV et al.. “Colchicine for acute gout.” The Cochrane database of systematic reviews (2021). PMID: 34438469 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors - [110]
Kydd AS, Seth R, Buchbinder R et al.. “Uricosuric medications for chronic gout.” The Cochrane database of systematic reviews (2014). PMID: 25392987 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Special Populations, Pregnancy & Prevention - [111]
Seth R, Kydd AS, Buchbinder R et al.. “Allopurinol for chronic gout.” The Cochrane database of systematic reviews (2014). PMID: 25314636 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Special Populations, Pregnancy & Prevention - [112]
Jackson G, Wright C, Thornley S et al.. “Potential unmet need for gout diagnosis and treatment: capture-recapture analysis of a national administrative dataset.” Rheumatology (Oxford, England) (2012). PMID: 22723595 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors - [113]
Abhishek A, Doherty M. “Education and non-pharmacological approaches for gout.” Rheumatology (Oxford, England) (2018). PMID: 29272507 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors - [114]
Doherty M. “New insights into the epidemiology of gout.” Rheumatology (Oxford, England) (2009). PMID: 19447779 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging & Classification Criteria - [115]
Singh G, Lingala B, Mithal A. “Gout and hyperuricaemia in the USA: prevalence and trends.” Rheumatology (Oxford, England) (2019). PMID: 31168609 ↗
L4OTHERCited in: Epidemiology, Etiology & Risk Factors - [116]
Dehlin M, Jacobsson L, Roddy E. “Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors.” Nature reviews. Rheumatology (2020). PMID: 32541923 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Complications: Disease-Driven & Treatment-Related - [117]
Gérard B, Leask M, Merriman TR et al.. “Hyperuricaemia and gout in the Pacific.” Nature reviews. Rheumatology (2025). PMID: 40069386 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors - [118]
Kuo CF, Grainge MJ, Zhang W et al.. “Global epidemiology of gout: prevalence, incidence and risk factors.” Nature reviews. Rheumatology (2015). PMID: 26150127 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors - [119]
Karacabeyli D, Lacaille D. “Glucagon-like peptide-1 receptor agonists in arthritis: current insights and future directions.” Nature reviews. Rheumatology (2025). PMID: 41034339 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Severity, Disease Activity & Risk Stratification, Prognosis & Natural History - [120]
Rees F, Hui M, Doherty M. “Optimizing current treatment of gout.” Nature reviews. Rheumatology (2014). PMID: 24614592 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors - [121]
Yokose C, McCormick N, Abhishek A et al.. “The clinical benefits of sodium-glucose cotransporter type 2 inhibitors in people with gout.” Nature reviews. Rheumatology (2024). PMID: 38472344 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Acute Management: Flares & Organ-Threatening Disease, Complications: Disease-Driven & Treatment-Related, Prognosis & Natural History - [122]
Richette P, Perez-Ruiz F, Doherty M et al.. “Improving cardiovascular and renal outcomes in gout: what should we target?” Nature reviews. Rheumatology (2014). PMID: 25136785 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Prognosis & Natural History - [123]
Terkeltaub R. “Update on gout: new therapeutic strategies and options.” Nature reviews. Rheumatology (2010). PMID: 20046204 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Special Populations, Pregnancy & Prevention - [124]
Choi HS, Heo J, Won S et al.. “Association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident Gout Risk: A Population-Based Comparative Cohort Study With Genetic Evidence From Mendelian Randomisation.” Diabetes, obesity & metabolism (2026). PMID: 42324202 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors - [125]
Palomäki A, Langén V, Airaksinen KEJ et al.. “Gout and Risk of Ischemic Stroke in Patients With Atrial Fibrillation: A Nationwide Cohort Study.” Stroke (2026). PMID: 42267424 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Complications: Disease-Driven & Treatment-Related - [126]
Lee JI, Park JW, Park CM et al.. “Risk factors for idiopathic cubital tunnel syndrome : development and surgical intervention from a nationwide population-based cohort study.” The bone & joint journal (2026). PMID: 42061880 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Special Populations, Pregnancy & Prevention - [127]
Guo K, Li C, Terkeltaub R et al.. “Effects of adding urinary alkalizer citrate mixture to febuxostat in gout patients with combined-type hyperuricemia and low urine pH: a prospective cohort study.” Arthritis research & therapy (2026). PMID: 41709338 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Acute Management: Flares & Organ-Threatening Disease - [128]
Pei H, He L, Wang S et al.. “Association between gout and cardiovascular disease: A register-based cohort study.” Progress in cardiovascular diseases (2026). PMID: 41707824 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Special Populations, Pregnancy & Prevention - [129]
Kapetanovic MC, Hameed M, Turkiewicz A et al.. “Prevalence and incidence of gout in southern Sweden from the socioeconomic perspective.” RMD open (2016). PMID: 27933209 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors - [130]
Sigurdardottir V, Jacobsson L, Schiöler L et al.. “Occupational exposure to inorganic dust and risk of gout: a population-based study.” RMD open (2020). PMID: 32683325 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors - [131]
Landgren AJ, Dehlin M, Jacobsson L et al.. “Cardiovascular risk factors in gout, psoriatic arthritis, rheumatoid arthritis and ankylosing spondylitis: a cross-sectional survey of patients in Western Sweden.” RMD open (2021). PMID: 34031261 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Complications: Disease-Driven & Treatment-Related - [132]
Te Kampe R, Boonen A, Jansen T et al.. “Development of a patient decision aid for the initiation of urate-lowering therapy in gout patients.” RMD open (2022). PMID: 35185008 ↗
L5OTHERCited in: Epidemiology, Etiology & Risk Factors, Severity, Disease Activity & Risk Stratification - [133]
Zhang W, Doherty M, Pascual E et al.. “EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).” Annals of the rheumatic diseases (2006). PMID: 16707533 ↗
L1GUIDELINECited in: Clinical Presentation - [134]
Nakayama A, Nakatochi M, Kawamura Y et al.. “Subtype-specific gout susceptibility loci and enrichment of selection pressure on ABCG2 and ALDH2 identified by subtype genome-wide meta-analyses of clinically defined gout patients.” Annals of the rheumatic diseases (2020). PMID: 32238385 ↗
L3SR_OBSCited in: Clinical Presentation, Prognosis & Natural History, Special Populations, Pregnancy & Prevention - [135]
Xu H, Liu Z, Zhou X et al.. “Deconstruction of tophi and synovium defines SPP1+ macrophages involved in extracellular matrix remodelling in gout.” Annals of the rheumatic diseases (2025). PMID: 41107120 ↗
L4OTHERCited in: Clinical Presentation, Acute Management: Flares & Organ-Threatening Disease - [136]
Filippou G, Pezzoni L, Filippucci E et al.. “Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions for disease elements in calcium pyrophosphate crystal deposition (CPPD).” Annals of the rheumatic diseases (2026). PMID: 42264993 ↗
L5OTHERCited in: Clinical Presentation, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target - [137]
Kang EH, Lee EY, Lee YJ et al.. “Clinical features and risk factors of postsurgical gout.” Annals of the rheumatic diseases (2007). PMID: 17998214 ↗
L3OTHERCited in: Clinical Presentation - [138]
Renaudin F, Orliaguet L, Castelli F et al.. “Gout and pseudo-gout-related crystals promote GLUT1-mediated glycolysis that governs NLRP3 and interleukin-1β activation on macrophages.” Annals of the rheumatic diseases (2020). PMID: 32699039 ↗
L5OTHERCited in: Clinical Presentation - [139]
Han L, Li R, Lu J et al.. “Association of the Quantity, Duration, and Type of Alcohol Consumption on the Development of Gouty Tophi.” Arthritis care & research (2022). PMID: 35695775 ↗
L4OTHERCited in: Clinical Presentation - [140]
Pascart T, Norberciak L, Ea HK et al.. “Patients With Early-Onset Gout and Development of Earlier Severe Joint Involvement and Metabolic Comorbid Conditions: Results From a Cross-Sectional Epidemiologic Survey.” Arthritis care & research (2019). PMID: 30022604 ↗
L2OTHERCited in: Clinical Presentation - [141]
Ghosh P, Cho M, Rawat G et al.. “Treatment of acute gouty arthritis in complex hospitalized patients with anakinra.” Arthritis care & research (2013). PMID: 23650178 ↗
L4OTHERCited in: Clinical Presentation - [142]
Pagnini I, Borsini W, Cecchi F et al.. “Distal extremity pain as a presenting feature of Fabry's disease.” Arthritis care & research (2010). PMID: 20981813 ↗
L4OTHERCited in: Clinical Presentation - [143]
Kissin EY, Nishio J, Yang M et al.. “Self-directed learning of basic musculoskeletal ultrasound among rheumatologists in the United States.” Arthritis care & research (2010). PMID: 20191513 ↗
L4OTHERCited in: Clinical Presentation - [144]
Zikánová M, Wahezi D, Hay A et al.. “Clinical manifestations and molecular aspects of phosphoribosylpyrophosphate synthetase superactivity in females.” Rheumatology (Oxford, England) (2018). PMID: 30423175 ↗
L4CASE_REPORTCited in: Clinical Presentation - [145]
Dalbeth N, Becce F, Botson JK et al.. “Dual-energy CT assessment of rapid monosodium urate depletion and bone erosion remodelling during pegloticase plus methotrexate co-therapy.” Rheumatology (Oxford, England) (2022). PMID: 35293984 ↗
L4CASE_REPORTCited in: Clinical Presentation - [146]
Schlesinger N, Schumacher R, Catton M et al.. “Colchicine for acute gout.” The Cochrane database of systematic reviews (2006). PMID: 17054279 ↗
L1SR_OBSCited in: Clinical Presentation, Severity, Disease Activity & Risk Stratification - [147]
Zhu H, Ni H, Yang Q et al.. “Evaluating the Bidirectional Causal Effects of Alzheimer's Disease Across Multiple Conditions: A Systematic Review and Meta-Analysis of Mendelian Randomization Studies.” International journal of molecular sciences (2025). PMID: 40332115 ↗
L2SR_OBSCited in: Clinical Presentation - [148]
Cavalli G, Dinarello CA. “Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies.” Rheumatology (Oxford, England) (2015). PMID: 26209330 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation - [149]
Ten Klooster PM, Kraiss JT, Munters R et al.. “Generalized pain hypersensitivity and associated factors in gout.” Rheumatology (Oxford, England) (2022). PMID: 34919669 ↗
L4OTHERCited in: Clinical Presentation, Severity, Disease Activity & Risk Stratification - [150]
Lin CY, Chang YS, Liu TY et al.. “Genetic contributions to female gout and hyperuricaemia using genome-wide association study and polygenic risk score analyses.” Rheumatology (Oxford, England) (2023). PMID: 35758599 ↗
L3OTHERCited in: Clinical Presentation - [151]
Stiburkova B, Pavelcova K, Zavada J et al.. “Functional non-synonymous variants of ABCG2 and gout risk.” Rheumatology (Oxford, England) (2017). PMID: 28968913 ↗
L3OTHERCited in: Clinical Presentation - [152]
Zhang L, Zhang W, Xiao C et al.. “Using human genetics to understand the epidemiological association between obesity, serum urate, and gout.” Rheumatology (Oxford, England) (2023). PMID: 36734534 ↗
L2OTHERCited in: Clinical Presentation - [153]
McCarthy GM, Dunne A. “Calcium crystal deposition diseases - beyond gout.” Nature reviews. Rheumatology (2018). PMID: 30190520 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Long-term Management: The DMARD Ladder & Treat-to-Target - [154]
Pardali EC, Gkouvi A, Nasiou K et al.. “Effect of Diet and Dietary Supplements on Gout-Related Outcomes: A Systematic Review of Randomised Controlled Trials.” Mediterranean journal of rheumatology (2025). PMID: 41647273 ↗
L1SR_MA_RCTCited in: Clinical Presentation, Acute Management: Flares & Organ-Threatening Disease - [155]
Felten R, Widawski L, Spielmann L et al.. “Impact of hyperuricaemia on patients with psoriatic arthritis treated with secukinumab in the FUTURE 2-5 and MAXIMISE studies.” RMD open (2023). PMID: 37945285 ↗
L2OTHERCited in: Clinical Presentation, Long-term Management: The DMARD Ladder & Treat-to-Target - [156]
Wang R, Xue Y, Wu Z et al.. “Prototheca wickerhamii causing toe infection presenting initially as gouty arthritis: A rare case report.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2025). PMID: 40914554 ↗
L4CASE_REPORTCited in: Clinical Presentation - [157]
Zheng Z, Yang C, Meng X et al.. “Case Report: Endovascular thrombectomy for acute ischemic stroke with bilateral internal carotid artery fibromuscular dysplasia.” Frontiers in cardiovascular medicine (2025). PMID: 40852205 ↗
L4CASE_REPORTCited in: Clinical Presentation - [158]
Wang H, Li X, Li B et al.. “Endoscopic management of lumbar spinal tophaceous gout: six cases treated with percutaneous transforaminal (PTED) and interlaminar (PIED) discectomy and a literature review.” European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society (2025). PMID: 40382497 ↗
L4CASE_REPORTCited in: Clinical Presentation - [159]
Majjad A, El Guarti S, Mansouri H et al.. “Psoriatic Arthritis Characteristics and Comorbidities in North Africa: Results of a Multicenter Retrospective Study.” Journal of psoriasis and psoriatic arthritis (2025). PMID: 41459256 ↗
L2COHORTCited in: Clinical Presentation - [160]
Borghi C, Fogacci F, Cicero AFG. “Urate-Lowering Therapy in Cardiovascular Pharmacotherapy: From Mendelian Randomization Data to Cardio-Renal-Metabolic Risk Modulation.” European heart journal. Cardiovascular pharmacotherapy (2026). PMID: 42308526 ↗
L5OTHERCited in: Clinical Presentation - [161]
Mandl P, D'Agostino MA, Navarro-Compán V et al.. “2023 EULAR recommendations on imaging in diagnosis and management of crystal-induced arthropathies in clinical practice.” Annals of the rheumatic diseases (2024). PMID: 38320811 ↗
L1GUIDELINECited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [162]
Stamp L, Horne A, Mihov B et al.. “Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial.” Annals of the rheumatic diseases (2023). PMID: 37652661 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History, Special Populations, Pregnancy & Prevention - [163]
Schlesinger N, Alten RE, Bardin T et al.. “Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions.” Annals of the rheumatic diseases (2012). PMID: 22586173 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History, Special Populations, Pregnancy & Prevention - [164]
Sun J, Wang Y, Cheng Y et al.. “Efficacy and Safety of Dotinurad Versus Febuxostat for the Treatment of Gout: A Randomized, Multicenter, Double-Blind, Phase 3 Trial in China.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 40417858 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History - [165]
Dalbeth N, Billington K, Doyle A et al.. “Effects of Allopurinol Dose Escalation on Bone Erosion and Urate Volume in Gout: A Dual-Energy Computed Tomography Imaging Study Within a Randomized, Controlled Trial.” Arthritis & rheumatology (Hoboken, N.J.) (2019). PMID: 31081595 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History - [166]
Saag KG, Khanna PP, Keenan RT et al.. “A Randomized, Phase II Study Evaluating the Efficacy and Safety of Anakinra in the Treatment of Gout Flares.” Arthritis & rheumatology (Hoboken, N.J.) (2021). PMID: 33605029 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History - [167]
Helget LN, O'Dell JR, Newcomb JA et al.. “Determinants of Achieving Serum Urate Goal with Treat-to-Target Urate-Lowering Therapy in Gout.” Arthritis & rheumatology (Hoboken, N.J.) (2023). PMID: 37842953 ↗
L2RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History - [168]
Stamp LK, Frampton C, Stewart S et al.. “Relationship Between Gout Flare States and Patient-Reported Outcomes After Allopurinol Initiation.” Arthritis care & research (2025). PMID: 39748204 ↗
L2RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History, Special Populations, Pregnancy & Prevention - [169]
Chohan S, Becker MA, MacDonald PA et al.. “Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.” Arthritis care & research (2012). PMID: 22052584 ↗
L2RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History - [170]
Stamp LK, Horne A, Mihov B et al.. “Colchicine Concentrations and Relationship With Colchicine Efficacy and Adverse Events: Post Hoc Analysis of a Randomized Clinical Trial of Colchicine for Gout Flare Prophylaxis.” Arthritis care & research (2025). PMID: 40223442 ↗
L2RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History - [171]
Chowalloor PV, Keen HI. “A systematic review of ultrasonography in gout and asymptomatic hyperuricaemia.” Annals of the rheumatic diseases (2013). PMID: 23291387 ↗
L2SR_OBSCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [172]
Gessl I, Sakellariou G, Wildner B et al.. “Systematic literature review to inform the EULAR recommendations for the use of imaging in crystal-induced arthropathies in clinical practice.” Annals of the rheumatic diseases (2024). PMID: 38702175 ↗
L2SR_OBSCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [173]
Moses A, Oude Voshaar MAH, van Geel EH et al.. “A treat-to-target strategy versus symptom-driven management of gout in the Netherlands (GO TEST Overture): a multicentre, open-label, pragmatic, superiority, randomised controlled trial.” The Lancet. Rheumatology (2026). PMID: 41865749 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History - [174]
Doherty M, Jenkins W, Richardson H et al.. “Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial.” Lancet (London, England) (2018). PMID: 30343856 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target - [175]
Mackenzie IS, Hawkey CJ, Ford I et al.. “Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial.” Lancet (London, England) (2022). PMID: 36216006 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History - [176]
Janssens HJ, Janssen M, van de Lisdonk EH et al.. “Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial.” Lancet (London, England) (2008). PMID: 18514729 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, Prognosis & Natural History - [177]
Badve SV, Pascoe EM, Tiku A et al.. “Effects of Allopurinol on the Progression of Chronic Kidney Disease.” The New England journal of medicine (2020). PMID: 32579811 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History - [178]
Wei J, Wang Y, Dalbeth N et al.. “Weight Loss After Receiving Anti-Obesity Medications and Gout Among Individuals With Overweight and Obese: A Population-Based Cohort Study.” Arthritis & rheumatology (Hoboken, N.J.) (2024). PMID: 39300602 ↗
L2COHORTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [179]
De Vera MA, Marcotte G, Rai S et al.. “Medication adherence in gout: a systematic review.” Arthritis care & research (2014). PMID: 24692321 ↗
L2SR_OBSCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Prognosis & Natural History - [180]
Hay CA, Prior JA, Belcher J et al.. “Mortality in Patients With Gout Treated With Allopurinol: A Systematic Review and Meta-Analysis.” Arthritis care & research (2021). PMID: 32286732 ↗
L2SR_OBSCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Prognosis & Natural History - [181]
Zeng L, Qasim A, Neogi T et al.. “Efficacy and Safety of Pharmacologic Interventions in Patients Experiencing a Gout Flare: A Systematic Review and Network Meta-Analysis.” Arthritis care & research (2021). PMID: 32741131 ↗
L1SR_OBSCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Prognosis & Natural History - [182]
Kelley GA, Kelley KS, Hootman JM et al.. “Effects of community-deliverable exercise on pain and physical function in adults with arthritis and other rheumatic diseases: a meta-analysis.” Arthritis care & research (2011). PMID: 20824798 ↗
L1SR_OBSCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [183]
Kim KH, Choi IA, Kim HJ et al.. “Familial Risk of Gout and Interaction With Obesity and Alcohol Consumption: A Population-Based Cohort Study in Korea.” Arthritis care & research (2023). PMID: 36714912 ↗
L2COHORTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [184]
Cipolletta E, Nakafero G, Rozza D et al.. “Development and validation of a prognostic model for predicting the risk of allopurinol-induced severe cutaneous adverse reactions: a retrospective new-user cohort study using linked primary care, hospitalisation, and mortality data.” The Lancet. Rheumatology (2025). PMID: 40915297 ↗
L2COHORTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Prognosis & Natural History - [185]
Saito Y, Tanaka A, Koide Y et al.. “Impact of febuxostat on visit-to-visit blood pressure variability: insights from the randomised PRIZE Study.” RMD open (2022). PMID: 36109083 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target - [186]
Tanaka A, Toyoda S, Kato T et al.. “Association between serum urate level and carotid atherosclerosis: an insight from a post hoc analysis of the PRIZE randomised clinical trial.” RMD open (2022). PMID: 35410947 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target - [187]
Dey M, Al-Attar M, Peruffo L et al.. “Assessment and diagnosis of the acute hot joint: a systematic review and meta-analysis.” Rheumatology (Oxford, England) (2023). PMID: 36264140 ↗
L2SR_OBSCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Complications: Disease-Driven & Treatment-Related - [188]
Chandratre P, Roddy E, Clarson L et al.. “Health-related quality of life in gout: a systematic review.” Rheumatology (Oxford, England) (2013). PMID: 23934311 ↗
L2SR_OBSCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [189]
Gwinnutt JM, Wieczorek M, Cavalli G et al.. “Effects of physical exercise and body weight on disease-specific outcomes of people with rheumatic and musculoskeletal diseases (RMDs): systematic reviews and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs.” RMD open (2022). PMID: 35361692 ↗
L2SR_OBSCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification - [190]
Wu Y, Chen K, Terkeltaub R. “Systematic review and quality analysis of emerging diagnostic measures for calcium pyrophosphate crystal deposition disease.” RMD open (2016). PMID: 27933211 ↗
L2SR_OBSCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [191]
Lan Z, Chen L, Feng J et al.. “Mechanosensitive TRPV4 is required for crystal-induced inflammation.” Annals of the rheumatic diseases (2021). PMID: 34663597 ↗
L5OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [192]
. “Correction.” Annals of the rheumatic diseases (2016). PMID: 26881284 ↗
L5OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [193]
Pascual E, Perdiguero M. “Gout, diuretics and the kidney.” Annals of the rheumatic diseases (2006). PMID: 16837492 ↗
L5OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [194]
Shen X, Wang C, Liang N et al.. “Serum Metabolomics Identifies Dysregulated Pathways and Potential Metabolic Biomarkers for Hyperuricemia and Gout.” Arthritis & rheumatology (Hoboken, N.J.) (2021). PMID: 33760368 ↗
L3OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [195]
Perry TA, O'Neill TW, Tolstykh I et al.. “Magnetic Resonance Imaging-Assessed Subchondral Cysts and Incident Knee Pain and Knee Osteoarthritis: Data From the Multicenter Osteoarthritis Study.” Arthritis & rheumatology (Hoboken, N.J.) (2021). PMID: 34224660 ↗
L2OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [196]
Christensen R, Zobbe K, Nielsen SM et al.. “Weight Loss for Patients With Gout and Concomitant Obesity: A Proof-of-Concept Randomized Trial.” Arthritis & rheumatology (Hoboken, N.J.) (2024). PMID: 38169151 ↗
L1OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [197]
Karlsson T, Hadizadeh F, Rask-Andersen M et al.. “Body Mass Index and the Risk of Rheumatic Disease: Linear and Nonlinear Mendelian Randomization Analyses.” Arthritis & rheumatology (Hoboken, N.J.) (2023). PMID: 37219954 ↗
L2OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [198]
Sun W, Li R, Dalbeth N et al.. “Metabolomic profiles underlying gout flares: a prospective study of people with gout.” RMD open (2025). PMID: 40345707 ↗
L2COHORTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease - [199]
Jackson LE, Annapureddy N, Hansen ME et al.. “Development and Validation of an Emergency Department Electronic Medical Record Gout Flare Alert.” Arthritis care & research (2023). PMID: 36408730 ↗
L3OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease - [200]
Burke BT, Köttgen A, Law A et al.. “Physical Function, Hyperuricemia, and Gout in Older Adults.” Arthritis care & research (2015). PMID: 26138016 ↗
L4OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [201]
Dalbeth N, Gosling AL, Gaffo A et al.. “Gout.” Lancet (London, England) (2021). PMID: 33798500 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Special Populations, Pregnancy & Prevention - [202]
Dalbeth N, Merriman TR, Stamp LK. “Gout.” Lancet (London, England) (2016). PMID: 27112094 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target - [203]
Guo K, Sun M, Hu S et al.. “Efficacy and safety of activated charcoal in primary gout: A double-blind, double-dummy, randomized controlled trial.” The American journal of medicine (2026). PMID: 41547464 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Prognosis & Natural History - [204]
Dalbeth N, Doyle AJ. “Imaging tools to measure treatment response in gout.” Rheumatology (Oxford, England) (2018). PMID: 29272513 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [205]
McDonnell T, Ioannou Y, Rahman A. “PEGylated drugs in rheumatology--why develop them and do they work?” Rheumatology (Oxford, England) (2013). PMID: 23962623 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Complications: Disease-Driven & Treatment-Related - [206]
Cipolletta E, Abhishek A, Di Battista J et al.. “Ultrasonography in the prediction of gout flares: a 12-month prospective observational study.” Rheumatology (Oxford, England) (2023). PMID: 35920773 ↗
L2OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [207]
Thiele RG, Schlesinger N. “Diagnosis of gout by ultrasound.” Rheumatology (Oxford, England) (2007). PMID: 17468505 ↗
L3OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [208]
Perez-Ruiz F. “Treating to target: a strategy to cure gout.” Rheumatology (Oxford, England) (2009). PMID: 19447780 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [209]
Kiely PDW, Lloyd ME. “Ankle arthritis - an important signpost in rheumatologic practice.” Rheumatology (Oxford, England) (2021). PMID: 33097958 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Complications: Disease-Driven & Treatment-Related - [210]
Stamp L, Dalbeth N. “Screening for hyperuricaemia and gout: a perspective and research agenda.” Nature reviews. Rheumatology (2014). PMID: 25136783 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [211]
Stamp LK, Day RO, Yun J. “Allopurinol hypersensitivity: investigating the cause and minimizing the risk.” Nature reviews. Rheumatology (2015). PMID: 26416594 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Prognosis & Natural History - [212]
McQueen FM. “Gout in 2013. Imaging, genetics and therapy: gout research continues apace.” Nature reviews. Rheumatology (2013). PMID: 24275962 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [213]
Dalbeth N, Bardin T, Doherty M et al.. “Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN).” Nature reviews. Rheumatology (2017). PMID: 28794514 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History - [214]
Pascual E, Addadi L, Andrés M et al.. “Mechanisms of crystal formation in gout-a structural approach.” Nature reviews. Rheumatology (2015). PMID: 26369610 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [215]
Singh JA. “Crystal arthritis: Is HLAB genotyping the future of gout pharmacogenomics?” Nature reviews. Rheumatology (2013). PMID: 23399693 ↗
L5OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Prognosis & Natural History - [216]
Borghi C, Piani F, Manolis AL. “Comprehensive Review on Febuxostat for Hyperuricemia with Gout: Insights from Current Practice and Clinical Trials.” High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension (2025). PMID: 41452447 ↗
L5TRIAL_NONRANDOMCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [217]
Zhao SS, Bowes J, Barton A et al.. “Separating the effects of childhood and adult body size on inflammatory arthritis: a Mendelian randomisation study.” RMD open (2022). PMID: 35995490 ↗
L2OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [218]
Laurent V, Jauffret C, Pacaud A et al.. “Factors influencing the kinetics of MSU crystal depletion measured with dual-energy CT in patients with gout.” RMD open (2023). PMID: 37940341 ↗
L2OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [219]
Bürgisser N, Chalot E, Mehouachi S et al.. “Large language models for accurate disease detection in electronic health records: the examples of crystal arthropathies.” RMD open (2024). PMID: 39794274 ↗
L3OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [220]
Uhlig T, Karoliussen LF, Sexton J et al.. “12-month results from the real-life observational treat-to-target and tight-control therapy NOR-Gout study: achievements of the urate target levels and predictors of obtaining this target.” RMD open (2021). PMID: 33782189 ↗
L2OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History - [221]
Christiansen SN, Østergaard M, Slot O et al.. “Assessing the sensitivity to change of the OMERACT ultrasound structural gout lesions during urate-lowering therapy.” RMD open (2020). PMID: 32396518 ↗
L2OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification - [222]
Luo J, Xie Z, Zhang W et al.. “Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein as Treatment for Gout Flare.” International journal of rheumatic diseases (2026). PMID: 41949339 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target - [223]
Pérez-López FR, Fernández-Alonso AM, Aidé S. “Meta-analysis of handgrip strength in subjects with high-normal or mildly increased uric acid compared to low-normal levels reported as quartiles.” Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology (2026). PMID: 41486688 ↗
L2SR_OBSCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [224]
Hwang J, Lee MY, Ahn JK. “Opposing associations of muscle and fat mass changes on serum uric acid levels: a 2-year longitudinal cohort study.” The Korean journal of internal medicine (2026). PMID: 42128394 ↗
L2COHORTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [225]
Jiang S, Lin L, Duan X et al.. “Indobufen versus aspirin in dual antiplatelet therapy: a retrospective study of effects on serum uric acid levels and gout attacks in patients post-coronary stenting.” PeerJ (2026). PMID: 41918864 ↗
L3COHORTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [226]
Tan J, Huang H, Tan L et al.. “Firsekibart for steroid withdrawal in glucocorticoid-dependent refractory gout: a case report.” Frontiers in immunology (2026). PMID: 41953015 ↗
L4CASE_REPORTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [227]
Eliseev MS, Chikina MN, Kuzmina YI et al.. “Efficacy and Safety of Long-term Administration of Various Doses of Colchicine in Patients with Gout.” Doklady. Biochemistry and biophysics (2026). PMID: 41912854 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target - [228]
Zhang MR, Hu JH, Guan JH et al.. “Gout of the iliopsoas muscle combined with tuberculosis infection causing persistent fever: a case report and literature review.” Frontiers in medicine (2026). PMID: 41561972 ↗
L4CASE_REPORTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Complications: Disease-Driven & Treatment-Related - [229]
Gamboa S, Shenvi C. “The great imitator: Hyperkalemia presenting with paralysis and ST segment elevations.” The American journal of emergency medicine (2025). PMID: 41274182 ↗
L4CASE_REPORTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [230]
Murdoch R, Pearcy Q, Schauer C et al.. “Tophus measurement as an outcome measure in gout: an updated systematic literature review.” Seminars in arthritis and rheumatism (2026). PMID: 42190485 ↗
L2REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria - [231]
FitzGerald JD, Dalbeth N, Mikuls T et al.. “2020 American College of Rheumatology Guideline for the Management of Gout.” Arthritis & rheumatology (Hoboken, N.J.) (2020). PMID: 32390306 ↗
L1GUIDELINECited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target - [232]
FitzGerald JD, Dalbeth N, Mikuls T et al.. “2020 American College of Rheumatology Guideline for the Management of Gout.” Arthritis care & research (2020). PMID: 32391934 ↗
L1GUIDELINECited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target - [233]
Singh JA, Yang S, Strand V et al.. “Validation of pain and patient global scales in chronic gout: data from two randomised controlled trials.” Annals of the rheumatic diseases (2011). PMID: 21622774 ↗
L2RCTCited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target - [234]
Barry A, Helget LN, Androsenko M et al.. “Comparison of Gout Flares With the Initiation of Treat-to-Target Allopurinol and Febuxostat: A Post-Hoc Analysis of a Randomized Multicenter Trial.” Arthritis & rheumatology (Hoboken, N.J.) (2024). PMID: 38925627 ↗
L2RCTCited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target - [235]
Dalbeth N, Doyle AJ, Billington K et al.. “Intensive Serum Urate Lowering With Oral Urate-Lowering Therapy for Erosive Gout: A Randomized Double-Blind Controlled Trial.” Arthritis & rheumatology (Hoboken, N.J.) (2022). PMID: 34927391 ↗
L1RCTCited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target - [236]
Gaffo AL, Calhoun DA, Rahn EJ et al.. “Effect of Serum Urate Lowering With Allopurinol on Blood Pressure in Young Adults: A Randomized, Controlled, Crossover Trial.” Arthritis & rheumatology (Hoboken, N.J.) (2021). PMID: 33779064 ↗
L1RCTCited in: Severity, Disease Activity & Risk Stratification - [237]
Barry A, England BR, Sayles H et al.. “Improvements in Health-Related Quality of Life With Treat-to-Target Urate-Lowering Therapy in Gout: A Post Hoc Analysis of a Randomized Multicenter Trial.” Arthritis care & research (2025). PMID: 40771143 ↗
L2RCTCited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target - [238]
Tabi-Amponsah AD, Stewart S, Gamble G et al.. “Baseline Dual-Energy Computed Tomography Urate Volume Predicts Fulfillment of Gout Remission After Two Years of Urate-Lowering Therapy.” Arthritis care & research (2024). PMID: 39135446 ↗
L2RCTCited in: Severity, Disease Activity & Risk Stratification - [239]
Stamp LK, Frampton C, Morillon MB et al.. “Association between serum urate and flares in people with gout and evidence for surrogate status: a secondary analysis of two randomised controlled trials.” The Lancet. Rheumatology (2021). PMID: 38288731 ↗
L2RCTCited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target - [240]
Cao C, Gamble G, Horne A et al.. “The Tophus Impact Questionnaire (TIQ-20): responsiveness to change during urate-lowering therapy.” Rheumatology (Oxford, England) (2024). PMID: 37688559 ↗
L2RCTCited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target - [241]
Russell MD, Clarke BD, Roddy E et al.. “Improving outcomes for patients hospitalized with gout: a systematic review.” Rheumatology (Oxford, England) (2021). PMID: 34247233 ↗
L2SR_OBSCited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Special Populations, Pregnancy & Prevention - [242]
Russell MD, Roddy E, Rutherford AI et al.. “Treat-to-target urate-lowering therapy and hospitalizations for gout: results from a nationwide cohort study in England.” Rheumatology (Oxford, England) (2023). PMID: 36355461 ↗
L2COHORTCited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target - [243]
Gwinnutt JM, Wieczorek M, Rodríguez-Carrio J et al.. “Effects of diet on the outcomes of rheumatic and musculoskeletal diseases (RMDs): systematic review and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs.” RMD open (2022). PMID: 35654458 ↗
L1SR_OBSCited in: Severity, Disease Activity & Risk Stratification - [244]
Wieczorek M, Gwinnutt JM, Ransay-Colle M et al.. “Smoking, alcohol consumption and disease-specific outcomes in rheumatic and musculoskeletal diseases (RMDs): systematic reviews informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs.” RMD open (2022). PMID: 35351808 ↗
L2SR_OBSCited in: Severity, Disease Activity & Risk Stratification - [245]
Drosos GC, Vedder D, Houben E et al.. “EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome.” Annals of the rheumatic diseases (2022). PMID: 35110331 ↗
L1OTHERCited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Complications: Disease-Driven & Treatment-Related - [246]
Gwinnutt JM, Wieczorek M, Balanescu A et al.. “2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases.” Annals of the rheumatic diseases (2022). PMID: 35260387 ↗
L1REVIEW_NARRATIVECited in: Severity, Disease Activity & Risk Stratification - [247]
Ea HK, Kischkel B, Chirayath TW et al.. “Systemic inflammatory cytokine profiles in patients with gout during flare, intercritical and treat-to-target phases: TNFSF14 as new biomarker.” Annals of the rheumatic diseases (2024). PMID: 38373842 ↗
L2OTHERCited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target - [248]
Hammer HB, Karoliussen L, Terslev L et al.. “Ultrasound-detected crystal depositions and clinical flares dissolve during successful urate-lowering therapy: 5-year follow-up results from the treat-to-target NOR-Gout study.” Annals of the rheumatic diseases (2025). PMID: 41271521 ↗
L2OTHERCited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target - [249]
Dalbeth N, Stamp L. “Hyperuricaemia and gout: time for a new staging system?” Annals of the rheumatic diseases (2014). PMID: 24718961 ↗
L5OTHERCited in: Severity, Disease Activity & Risk Stratification - [250]
Sun W, Xu L, Chen H et al.. “A Metabolomic Signature Predicts Gout Flare Clinical Outcome Associated With Colchicine Prophylaxis.” Arthritis & rheumatology (Hoboken, N.J.) (2026). PMID: 41711532 ↗
L2OTHERCited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target - [251]
Holzinger D, Nippe N, Vogl T et al.. “Myeloid-related proteins 8 and 14 contribute to monosodium urate monohydrate crystal-induced inflammation in gout.” Arthritis & rheumatology (Hoboken, N.J.) (2014). PMID: 24470119 ↗
L5OTHERCited in: Severity, Disease Activity & Risk Stratification - [252]
Kwok TSH, Kuriya B, Hawker G et al.. “Adherence and Treat-to-Target Benchmarks in Older Adults With Gout Initiating Urate-Lowering Therapy in Ontario, Canada: A Population-Based Study.” Arthritis care & research (2024). PMID: 38831665 ↗
L2OTHERCited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target - [253]
Chiou A, England BR, Sayles H et al.. “Coexistent Hyperuricemia and Gout in Rheumatoid Arthritis: Associations With Comorbidities, Disease Activity, and Mortality.” Arthritis care & research (2020). PMID: 31074584 ↗
L2OTHERCited in: Severity, Disease Activity & Risk Stratification - [254]
Wang X, Xie Y, Zhu X et al.. “Clinical study of the pharmacokinetics and pharmacodynamics of Xininurad tablets in patients with renal impairment.” British journal of clinical pharmacology (2025). PMID: 40954546 ↗
L2TRIAL_NONRANDOMCited in: Severity, Disease Activity & Risk Stratification - [255]
Perez-Ruiz F, Moreno-Lledó A, Urionagüena I et al.. “Treat to target in gout.” Rheumatology (Oxford, England) (2018). PMID: 29272512 ↗
L5REVIEW_NARRATIVECited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target - [256]
Wheeler AM, Ourada TJ, Jones SQ et al.. “Systemic inflammation in gout and the impact of treat-to-target urate-lowering therapy.” Rheumatology (Oxford, England) (2025). PMID: 41390970 ↗
L3OTHERCited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Special Populations, Pregnancy & Prevention - [257]
Russell MD, Ameyaw-Kyeremeh L, Dell'Accio F et al.. “Implementing treat-to-target urate-lowering therapy during hospitalizations for gout flares.” Rheumatology (Oxford, England) (2024). PMID: 37929968 ↗
L2OTHERCited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target - [258]
Stamp LK, Dalbeth N. “Critical appraisal of serum urate targets in the management of gout.” Nature reviews. Rheumatology (2022). PMID: 35974164 ↗
L5REVIEW_NARRATIVECited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target - [259]
Klionsky Y, Torralba KD, Obermeyer K et al.. “Gout Remission With Pegloticase-Induced Intensive Urate-Lowering Therapy: A Post Hoc Clinical Trial Analysis.” ACR open rheumatology (2025). PMID: 40810458 ↗
L1TRIAL_NONRANDOMCited in: Severity, Disease Activity & Risk Stratification - [260]
Uhlig T, Karoliussen LF, Sexton J et al.. “Lifestyle factors predict gout outcomes: Results from the NOR-Gout longitudinal 2-year treat-to-target study.” RMD open (2023). PMID: 38053463 ↗
L2OTHERCited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target - [261]
Richette P, Doherty M, Pascual E et al.. “2016 updated EULAR evidence-based recommendations for the management of gout.” Annals of the rheumatic diseases (2016). PMID: 27457514 ↗
L1GUIDELINECited in: Acute Management: Flares & Organ-Threatening Disease - [262]
Terkeltaub R, Lee J, Min J et al.. “Serum Urate-Lowering Efficacy and Safety of Tigulixostat in Gout Patients With Hyperuricemia: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Trial.” Arthritis & rheumatology (Hoboken, N.J.) (2023). PMID: 36649008 ↗
L1RCTCited in: Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History - [263]
Saag KG, Becker MA, Whelton A et al.. “Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study.” Arthritis & rheumatology (Hoboken, N.J.) (2019). PMID: 30073793 ↗
L1RCTCited in: Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target - [264]
Stamp LK, Horne A, Mihov B et al.. “Predicting Gout Flares in People Starting Allopurinol Using the Start-Low Go-Slow Dose Escalation Strategy.” Arthritis care & research (2024). PMID: 38766703 ↗
L1RCTCited in: Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target - [265]
Watson L, Belcher J, Nicholls E et al.. “Latent Class Growth Analysis of Gout Flare Trajectories: A Three-Year Prospective Cohort Study in Primary Care.” Arthritis & rheumatology (Hoboken, N.J.) (2020). PMID: 32767502 ↗
L2COHORTCited in: Acute Management: Flares & Organ-Threatening Disease - [266]
Stamp LK, Frampton C, Newcomb JA et al.. “Gout Flares After Stopping Anti-Inflammatory Prophylaxis: A Rapid Literature Review and Meta-Analysis.” Arthritis care & research (2025). PMID: 39711080 ↗
L1SR_OBSCited in: Acute Management: Flares & Organ-Threatening Disease - [267]
Jia E, Zhang Y, Ma W et al.. “Initiation of febuxostat for acute gout flare does not prolong the current episode: a randomized clinical trial.” Rheumatology (Oxford, England) (2021). PMID: 33404656 ↗
L1RCTCited in: Acute Management: Flares & Organ-Threatening Disease - [268]
Cipolletta E, Nakafero G, McCormick N et al.. “Cardiovascular events in patients with gout initiating urate-lowering therapy with or without colchicine for flare prophylaxis: a retrospective new-user cohort study using linked primary care, hospitalisation, and mortality data.” The Lancet. Rheumatology (2024). PMID: 39708831 ↗
L2COHORTCited in: Acute Management: Flares & Organ-Threatening Disease, Prognosis & Natural History - [269]
Hu S, Sun M, Li M et al.. “Elevated serum CA72-4 predicts gout flares during urate lowering therapy initiation: a prospective cohort study.” Rheumatology (Oxford, England) (2023). PMID: 36409036 ↗
L2COHORTCited in: Acute Management: Flares & Organ-Threatening Disease - [270]
Poulsen R, Dalbeth N. “Gout and NLRP3 Inflammasome Biology.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 40322858 ↗
L5REVIEW_NARRATIVECited in: Acute Management: Flares & Organ-Threatening Disease - [271]
Wang M, Li R, Qi H et al.. “Metabolomics and Machine Learning Identify Metabolic Differences and Potential Biomarkers for Frequent Versus Infrequent Gout Flares.” Arthritis & rheumatology (Hoboken, N.J.) (2023). PMID: 37390372 ↗
L3OTHERCited in: Acute Management: Flares & Organ-Threatening Disease - [272]
Dalbeth N, Frampton C, Fung M et al.. “Predictors of Patient and Physician Assessments of Gout Control.” Arthritis care & research (2022). PMID: 36263859 ↗
L4OTHERCited in: Acute Management: Flares & Organ-Threatening Disease - [273]
Li J, Badve SV, Zhou Z et al.. “The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program.” The Lancet. Rheumatology (2019). PMID: 38229378 ↗
L1OTHERCited in: Acute Management: Flares & Organ-Threatening Disease - [274]
Klück V, Jansen TLTA, Janssen M et al.. “Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial.” The Lancet. Rheumatology (2020). PMID: 33005902 ↗
L2OTHERCited in: Acute Management: Flares & Organ-Threatening Disease - [275]
Selvadurai D, Coleshill MJ, Day RO et al.. “Health outcomes associated with patient-perceived gout aetiology: a cross-sectional analysis of the GAPP Study baseline data.” Clinical rheumatology (2025). PMID: 41206822 ↗
L4RCTCited in: Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target - [276]
Andrés M, Sivera F, Buchbinder R et al.. “Dietary supplements for chronic gout.” The Cochrane database of systematic reviews (2021). PMID: 34767649 ↗
L1SR_OBSCited in: Acute Management: Flares & Organ-Threatening Disease, Complications: Disease-Driven & Treatment-Related, Special Populations, Pregnancy & Prevention - [277]
Sivera F, Wechalekar MD, Andrés M et al.. “Interleukin-1 inhibitors for acute gout.” The Cochrane database of systematic reviews (2014). PMID: 25177840 ↗
L1SR_OBSCited in: Acute Management: Flares & Organ-Threatening Disease - [278]
Wechalekar MD, Vinik O, Schlesinger N et al.. “Intra-articular glucocorticoids for acute gout.” The Cochrane database of systematic reviews (2013). PMID: 23633379 ↗
L1SR_OBSCited in: Acute Management: Flares & Organ-Threatening Disease - [279]
Andrés M, Sivera F, Falzon L et al.. “Dietary supplements for chronic gout.” The Cochrane database of systematic reviews (2014). PMID: 25287939 ↗
L1SR_OBSCited in: Acute Management: Flares & Organ-Threatening Disease, Complications: Disease-Driven & Treatment-Related, Special Populations, Pregnancy & Prevention - [280]
Yokose C, McCormick N, Lu N et al.. “Nationwide racial/ethnic disparities in US emergency department visits and hospitalizations for gout.” Rheumatology (Oxford, England) (2023). PMID: 36218483 ↗
L2OTHERCited in: Acute Management: Flares & Organ-Threatening Disease - [281]
Orji OC, López-Domínguez MB, Sandoval-Plata G et al.. “Upregulated expression of FFAR2 and SOC3 genes is associated with gout.” Rheumatology (Oxford, England) (2023). PMID: 35731142 ↗
L3OTHERCited in: Acute Management: Flares & Organ-Threatening Disease - [282]
Jagpal A, Rahn EJ, Mudano AS et al.. “Which factors predict discordance between a patient and physician on a gout flare?” Rheumatology (Oxford, England) (2021). PMID: 32793971 ↗
L3OTHERCited in: Acute Management: Flares & Organ-Threatening Disease - [283]
Choi HK, Zhang Y, Dalbeth N. “When underlying biology threatens the randomization principle - initial gout flares of urate-lowering therapy.” Nature reviews. Rheumatology (2022). PMID: 35879610 ↗
L5REVIEW_NARRATIVECited in: Acute Management: Flares & Organ-Threatening Disease, Special Populations, Pregnancy & Prevention - [284]
Chen R, Hu S, Lu S et al.. “Machine learning-based prediction of gout flares during hospitalization in patients with upper gastrointestinal bleeding: a retrospective cohort study.” Frontiers in medicine (2026). PMID: 42359073 ↗
L2COHORTCited in: Acute Management: Flares & Organ-Threatening Disease - [285]
Li M, Zhang H, Chen S et al.. “Development and validation of a multidimensional and interpretable artificial intelligence model to predict gout recurrence in hospitalised patients: a real-world, ambispective multicentre cohort study in China.” BMC medicine (2025). PMID: 41188838 ↗
L2COHORTCited in: Acute Management: Flares & Organ-Threatening Disease - [286]
Fan B, Ye Y, Wang Z et al.. “Establishment and evaluation of a model for clinical feature selection and prediction in gout patients with cardiovascular diseases: a retrospective cohort study.” Frontiers in endocrinology (2025). PMID: 41141353 ↗
L2COHORTCited in: Acute Management: Flares & Organ-Threatening Disease, Special Populations, Pregnancy & Prevention - [287]
Diaz-Torne C, Pou MA, Horne A et al.. “'Gout was like the boss'. A qualitative study exploring the impact of gout on employment.” RMD open (2024). PMID: 39160089 ↗
L4OTHERCited in: Acute Management: Flares & Organ-Threatening Disease - [288]
Bausson J, Keller N, Von Hunolstein JJ et al.. “Safety and efficacy of colchicine in crystal-induced arthritis flare in 54 patients with severe chronic kidney disease.” RMD open (2024). PMID: 38296804 ↗
L4OTHERCited in: Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related - [289]
Grassot J, Marzouki F, Hervé R et al.. “Intra-articular sustained-release colchicine is efficacious in an inflammatory arthritis rat model.” RMD open (2025). PMID: 41022524 ↗
L5OTHERCited in: Acute Management: Flares & Organ-Threatening Disease - [290]
Panagiotopoulos E, Kotsali-Peteinelli V, Papagiannopoulou G et al.. “Gout flares following acute stroke: a single-center cohort and a systematic review/meta-analysis.” Neurological research and practice (2025). PMID: 41094550 ↗
L2SR_OBSCited in: Acute Management: Flares & Organ-Threatening Disease - [291]
Sattar N, Scilletta S, Stefanski A et al.. “Tirzepatide and change in uric acid and its association with weight reduction: post hoc analyses of the SURMOUNT-1 randomised placebo-controlled trial.” Annals of the rheumatic diseases (2025). PMID: 41198460 ↗
L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History - [292]
Dalbeth N, Aati O, Gamble GD et al.. “Zoledronate for prevention of bone erosion in tophaceous gout: a randomised, double-blind, placebo-controlled trial.” Annals of the rheumatic diseases (2014). PMID: 24442886 ↗
L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, Special Populations, Pregnancy & Prevention - [293]
Stamp LK, Chapman PT, Barclay M et al.. “Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open-label extension study.” Annals of the rheumatic diseases (2017). PMID: 28830881 ↗
L2RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [294]
Bardin T, Keenan RT, Khanna PP et al.. “Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).” Annals of the rheumatic diseases (2016). PMID: 27821644 ↗
L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [295]
Reinders MK, van Roon EN, Jansen TL et al.. “Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.” Annals of the rheumatic diseases (2008). PMID: 18250112 ↗
L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [296]
Becker MA, Baraf HS, Yood RA et al.. “Long-term safety of pegloticase in chronic gout refractory to conventional treatment.” Annals of the rheumatic diseases (2012). PMID: 23144450 ↗
L2RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [297]
Dalbeth N, Saag KG, Palmer WE et al.. “Effects of Febuxostat in Early Gout: A Randomized, Double-Blind, Placebo-Controlled Study.” Arthritis & rheumatology (Hoboken, N.J.) (2017). PMID: 28975718 ↗
L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History - [298]
Yan F, Xue X, Lu J et al.. “Superiority of Low-Dose Benzbromarone to Low-Dose Febuxostat in a Prospective, Randomized Comparative Effectiveness Trial in Gout Patients With Renal Uric Acid Underexcretion.” Arthritis & rheumatology (Hoboken, N.J.) (2022). PMID: 35795968 ↗
L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [299]
Murdoch R, Mihov B, Horne AM et al.. “Impact of Television Depictions of Gout on Perceptions of Illness: A Randomized Controlled Trial.” Arthritis care & research (2023). PMID: 37038965 ↗
L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [300]
Pryymachenko Y, Wilson R, Dalbeth N et al.. “Cost-Effectiveness of Low-Dose Colchicine Prophylaxis When Starting Allopurinol Using the "Start-Low Go-Slow" Approach for Gout: Evidence From a Noninferiority Randomized Double-Blind Placebo-Controlled Trial.” Arthritis care & research (2025). PMID: 40827007 ↗
L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [301]
Xue X, Sun M, Yan F et al.. “Superiority of Low-Dose Benzbromarone Add-On to Low-Dose Febuxostat Compared With Febuxostat Monotherapy in Gout With Combined-Type Hyperuricemia.” Arthritis care & research (2024). PMID: 38130040 ↗
L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [302]
Pascart T, Robinet P, Ottaviani S et al.. “Evaluating the safety and short-term equivalence of colchicine versus prednisone in older patients with acute calcium pyrophosphate crystal arthritis (COLCHICORT): an open-label, multicentre, randomised trial.” The Lancet. Rheumatology (2023). PMID: 38251496 ↗
L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [303]
Tardif JC, Kouz S, Waters DD et al.. “Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.” The New England journal of medicine (2019). PMID: 31733140 ↗
L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [304]
White WB, Saag KG, Becker MA et al.. “Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.” The New England journal of medicine (2018). PMID: 29527974 ↗
L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, Prognosis & Natural History - [305]
Selvadurai D, Coleshill MJ, Day RO et al.. “Patient factors and health outcomes associated with illness perceptions in people with gout.” Rheumatology (Oxford, England) (2024). PMID: 37769230 ↗
L2RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [306]
Stamp LK, Chapman PT, Barclay M et al.. “Can we predict inadequate response to allopurinol dose escalation? Analysis of a randomised controlled trial.” Rheumatology (Oxford, England) (2018). PMID: 30107437 ↗
L2RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [307]
Hammam N, Li J, Kay J et al.. “Monitoring and Achievement of Target Serum Urate Among Gout Patients Receiving Long-Term Urate-Lowering Therapy in the American College of Rheumatology RISE Registry.” Arthritis care & research (2023). PMID: 36039961 ↗
L2OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [308]
Chitineni S, Solomon DH, Choi H et al.. “Assessing Reliability of an Electronic Gout Flare Assessment Protocol.” Arthritis care & research (2026). PMID: 42328908 ↗
L4OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [309]
Peeters IR, Veenstra F, Wanten SAC et al.. “Perspective of Dutch Patients with Gout on Continuation or Discontinuation of Urate-Lowering Therapy During Remission: A Mixed-Methods Study.” Arthritis care & research (2024). PMID: 38924379 ↗
L4OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [310]
Li T, Lu Z, Peng W et al.. “Oatmeal-based fiber diet outperforms resistant starch-based fiber diet in lowering serum uric acid via gut microbiota-metabolite interactions: a randomized controlled trial.” Food & function (2026). PMID: 42171138 ↗
L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [311]
Liu Y, Hua C, Wu Y et al.. “Evaluation of the clinical efficacy of Xanthoceras sorbifolium leaves in intervening in hyperuricemia and research on its uric acid-lowering mechanism.” Phytomedicine : international journal of phytotherapy and phytopharmacology (2026). PMID: 42160899 ↗
L4RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related - [312]
Jiang T, Ge L, Wang X et al.. “Development and testing of a smart empowerment education system for gout patients in suburban areas.” Frontiers in public health (2026). PMID: 42145497 ↗
L4RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [313]
Yong X, Du X, Li X et al.. “A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Phase 1 Study of Firsekibart in Chinese Healthy Participants.” Clinical pharmacology in drug development (2026). PMID: 41693373 ↗
L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [314]
Wang F, Ye X, Li F et al.. “Bioequivalence evaluation of generic febuxostat versus Feburic® in healthy Chinese subjects: a randomized crossover study.” BMC pharmacology & toxicology (2025). PMID: 41053902 ↗
L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [315]
Lioté F, Constantin A, Dahan É et al.. “A prospective survey on therapeutic inertia in psoriatic arthritis (OPTI'PsA).” Rheumatology (Oxford, England) (2024). PMID: 37261843 ↗
L5OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [316]
Christiansen SN, Østergaard M, Slot O et al.. “Retrospective longitudinal assessment of ultrasound gout lesions using the OMERACT semi-quantitative scoring system.” Rheumatology (Oxford, England) (2022). PMID: 35298610 ↗
L2OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [317]
Uhlig T, Karoliussen LF, Sexton J et al.. “Course and predictors of work productivity in gout - results from the NOR-Gout longitudinal 2-year treat-to-target study.” Rheumatology (Oxford, England) (2023). PMID: 36943375 ↗
L2OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [318]
Uhlig T, Eskild T, Karoliussen LF et al.. “Two-year reduction of dual-energy CT urate depositions during a treat-to-target strategy in gout in the NOR-Gout longitudinal study.” Rheumatology (Oxford, England) (2022). PMID: 34247224 ↗
L2OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [319]
Li N, Chen Z, Han M et al.. “Biological aging and gout risk in hyperuricemia: a UK Biobank cohort study.” International journal of surgery (London, England) (2025). PMID: 41347257 ↗
L2COHORTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Special Populations, Pregnancy & Prevention - [320]
Troum OM, Botson JK, Fang F et al.. “Safety, Tolerability, and Efficacy of Shorter Infusion Durations of Pegloticase Administered to Patients With Uncontrolled Gout Receiving Methotrexate: AGILE Trial.” Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases (2025). PMID: 40984755 ↗
L4TRIAL_NONRANDOMCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [321]
Abhishek A, Iagnocco A, Bijlsma JWJ et al.. “Cross-sectional survey of the undergraduate rheumatology curriculum in European medical schools: a EULAR School of Rheumatology initiative.” RMD open (2018). PMID: 30271621 ↗
L5OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related - [322]
Ding K, Zhu M, Zheng X et al.. “A Lipid- and Inflammation-Related Metabolite Risk Score Predicts Incident Gout Among Individuals With Hyperuricemia: A Prospective Cohort Study.” Clinical rheumatology (2026). PMID: 42101755 ↗
L2COHORTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [323]
Wang YC, Huang AP, Huang CW et al.. “Association Between Gout and the Risk of Dementia: A Meta-Analysis of Observational Studies and Biological Mechanisms.” International journal of rheumatic diseases (2026). PMID: 41782208 ↗
L2SR_OBSCited in: Long-term Management: The DMARD Ladder & Treat-to-Target - [324]
Tang X, Peng Y, Jiang Z et al.. “Efferocytosis and Its Role in Rheumatic Diseases.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 40452369 ↗
L5REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [325]
Fritsch-Stork RD, Leguit RJ, Derksen RH. “Rapidly fatal HTLV-1-associated T-cell leukemia/lymphoma in a patient with SLE.” Nature reviews. Rheumatology (2009). PMID: 19412195 ↗
L4CASE_REPORTCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [326]
Soricelli E, Quartararo G, Leuratti L et al.. “Effects of bariatric surgery on hyperuricemia and gout: a systematic review of the literature.” Updates in surgery (2024). PMID: 39520613 ↗
L5SR_OBSCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [327]
Lavielle M, Puyraimond-Zemmour D, Romand X et al.. “Methods to improve medication adherence in patients with chronic inflammatory rheumatic diseases: a systematic literature review.” RMD open (2018). PMID: 30116556 ↗
L2REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [328]
Frei S, Sanchez-Migallon Guzman D, Kass PH et al.. “Evaluation of a ventral and a left lateral approach to coelioscopy in bearded dragons (Pogona vitticeps).” American journal of veterinary research (2020). PMID: 32101045 ↗
L1RCTCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [329]
Magen E, Aamar S, Magen I et al.. “Long-term rheumatologic comorbidities in familial Mediterranean fever.” Seminars in arthritis and rheumatism (2026). PMID: 42250404 ↗
L2OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [330]
Han M, Wu R, Jin P et al.. “Molecular characterization and evolutionary analysis of a duck astrovirus type 3 strain.” Poultry science (2025). PMID: 41411853 ↗
L5OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [331]
Jiao X, Jin Q, Zhu P et al.. “Clerodendranthus spicatus: a comprehensive review of the chemical constituents, pharmacology, quality control and clinical applications.” Frontiers in pharmacology (2025). PMID: 40183086 ↗
L5REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [332]
Blau BJ, Mandl LA. “Rheumatology: What You May Have Missed in 2024.” Annals of internal medicine (2025). PMID: 40163867 ↗
L5REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [333]
Held J, Strolz C, Reijnierse M et al.. “Diagnostic Impact of Subcutaneous Edema in Gouty Feet Detected by Dual-Energy Computed Tomography and Ultrasound.” Journal of clinical medicine (2024). PMID: 39768543 ↗
L4OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [334]
Yan M, Du M, Yu T et al.. “Concordance of Ultrasound and Dual-Energy CT in Diagnosing Gouty Arthritis in the Knee Joint: A Retrospective Observational Study.” Academic radiology (2024). PMID: 39245598 ↗
L4OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [335]
Zhang Z, Wang P, Xiong Q et al.. “Advancements in the study of IL-6 and its receptors in the pathogenesis of gout.” Cytokine (2024). PMID: 39053079 ↗
L5REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map) - [336]
Dalbeth N, Horne A, Mihov B et al.. “Elevated Urate Levels Do Not Alter Bone Turnover Markers: Randomized Controlled Trial of Inosine Supplementation in Postmenopausal Women.” Arthritis & rheumatology (Hoboken, N.J.) (2021). PMID: 33586367 ↗
L1RCTCited in: Complications: Disease-Driven & Treatment-Related - [337]
Rho YH, Lu N, Peloquin CE et al.. “Independent impact of gout on the risk of diabetes mellitus among women and men: a population-based, BMI-matched cohort study.” Annals of the rheumatic diseases (2014). PMID: 25277955 ↗
L2COHORTCited in: Complications: Disease-Driven & Treatment-Related - [338]
Kang EH, Choi HK, Shin A et al.. “Comparative cardiovascular risk of allopurinol versus febuxostat in patients with gout: a nation-wide cohort study.” Rheumatology (Oxford, England) (2019). PMID: 31098635 ↗
L2COHORTCited in: Complications: Disease-Driven & Treatment-Related - [339]
Andrés M, Bernal JA, Sivera F et al.. “Cardiovascular risk of patients with gout seen at rheumatology clinics following a structured assessment.” Annals of the rheumatic diseases (2017). PMID: 28093417 ↗
L4OTHERCited in: Complications: Disease-Driven & Treatment-Related - [340]
Grimaldi-Bensouda L, Alpérovitch A, Aubrun E et al.. “Impact of allopurinol on risk of myocardial infarction.” Annals of the rheumatic diseases (2014). PMID: 24395556 ↗
L3OTHERCited in: Complications: Disease-Driven & Treatment-Related - [341]
Dubreuil M, Zhu Y, Zhang Y et al.. “Allopurinol initiation and all-cause mortality in the general population.” Annals of the rheumatic diseases (2014). PMID: 24665118 ↗
L2OTHERCited in: Complications: Disease-Driven & Treatment-Related - [342]
Rodríguez G, Soriano LC, Choi HK. “Impact of diabetes against the future risk of developing gout.” Annals of the rheumatic diseases (2010). PMID: 20570836 ↗
L3OTHERCited in: Complications: Disease-Driven & Treatment-Related - [343]
Chen JH, Wen CP, Wu SB et al.. “Attenuating the mortality risk of high serum uric acid: the role of physical activity underused.” Annals of the rheumatic diseases (2014). PMID: 25053714 ↗
L2OTHERCited in: Complications: Disease-Driven & Treatment-Related - [344]
Cleophas MC, Crişan TO, Lemmers H et al.. “Suppression of monosodium urate crystal-induced cytokine production by butyrate is mediated by the inhibition of class I histone deacetylases.” Annals of the rheumatic diseases (2015). PMID: 25589513 ↗
L5OTHERCited in: Complications: Disease-Driven & Treatment-Related - [345]
Xie D, Choi HK, Dalbeth N et al.. “Gout and Excess Risk of Severe SARS-CoV-2 Infection Among Vaccinated Individuals: A General Population Study.” Arthritis & rheumatology (Hoboken, N.J.) (2022). PMID: 36082457 ↗
L2OTHERCited in: Complications: Disease-Driven & Treatment-Related, Special Populations, Pregnancy & Prevention - [346]
Dellaripa PF, Sung LH, Bain PA et al.. “American College of Rheumatology White Paper: The Effects of Climate Change on Rheumatic Conditions-An Evolving Landscape and a Path Forward.” Arthritis & rheumatology (Hoboken, N.J.) (2024). PMID: 38751102 ↗
L1REVIEW_NARRATIVECited in: Complications: Disease-Driven & Treatment-Related - [347]
Kleiber Balderrama C, Rosenthal AK, Lans D et al.. “Calcium Pyrophosphate Deposition Disease and Associated Medical Comorbidities: A National Cross-Sectional Study of US Veterans.” Arthritis care & research (2017). PMID: 27898996 ↗
L3OTHERCited in: Complications: Disease-Driven & Treatment-Related - [348]
Rasooly D, Moonesinghe R, Fallon E et al.. “Family History of Arthritis, Osteoporosis, and Carpal Tunnel Syndrome and Risk of These Conditions Among US Adults.” Arthritis care & research (2024). PMID: 39155684 ↗
L4OTHERCited in: Complications: Disease-Driven & Treatment-Related, Special Populations, Pregnancy & Prevention - [349]
D'Silva KM, Yokose C, Lu N et al.. “Hypouricemia and Mortality Risk in the US General Population.” Arthritis care & research (2021). PMID: 33026684 ↗
L2OTHERCited in: Complications: Disease-Driven & Treatment-Related - [350]
Kelly A, Tymms K, de Wit M et al.. “Patient and Caregiver Priorities for Medication Adherence in Gout, Osteoporosis, and Rheumatoid Arthritis: Nominal Group Technique.” Arthritis care & research (2020). PMID: 31325214 ↗
L5OTHERCited in: Complications: Disease-Driven & Treatment-Related - [351]
McCormick N, Lin K, Yokose C et al.. “Unclosing Premature Mortality Gap Among Patients With Gout in the US General Population, Independent of Serum Urate and Atherosclerotic Cardiovascular Risk Factors.” Arthritis care & research (2024). PMID: 38191784 ↗
L2OTHERCited in: Complications: Disease-Driven & Treatment-Related - [352]
Singh JA, Cleveland JD. “Serious Infections in Patients With Gout in the US: A National Study of Incidence, Time Trends, and Outcomes.” Arthritis care & research (2021). PMID: 32248660 ↗
L3OTHERCited in: Complications: Disease-Driven & Treatment-Related - [353]
Singh JA, Richards JS, Chang E et al.. “Management of Rheumatic Diseases During the COVID-19 Pandemic: A National Veterans Affairs Survey of Rheumatologists.” Arthritis care & research (2021). PMID: 33058485 ↗
L4OTHERCited in: Complications: Disease-Driven & Treatment-Related - [354]
Janssens HJ, Lucassen PL, Van de Laar FA et al.. “Systemic corticosteroids for acute gout.” The Cochrane database of systematic reviews (2008). PMID: 18425920 ↗
L1SR_OBSCited in: Complications: Disease-Driven & Treatment-Related - [355]
Li P, Wang Q, Yang Y et al.. “Autoimmune thyroid disease and human health: a systematic review of Mendelian randomization studies.” Frontiers in immunology (2025). PMID: 41425574 ↗
L2SR_OBSCited in: Complications: Disease-Driven & Treatment-Related, Special Populations, Pregnancy & Prevention - [356]
Hughes M, Akram Q, Rees DC et al.. “Haemoglobinopathies and the rheumatologist.” Rheumatology (Oxford, England) (2016). PMID: 27018056 ↗
L5REVIEW_NARRATIVECited in: Complications: Disease-Driven & Treatment-Related - [357]
Baker JF, Ghio AJ. “Iron homoeostasis in rheumatic disease.” Rheumatology (Oxford, England) (2009). PMID: 19628641 ↗
L5REVIEW_NARRATIVECited in: Complications: Disease-Driven & Treatment-Related - [358]
Ghang B, Kim J, Kang T et al.. “Ten-year cardiovascular risk changes and major adverse events in gout patients.” Rheumatology (Oxford, England) (2026). PMID: 40971687 ↗
L3OTHERCited in: Complications: Disease-Driven & Treatment-Related - [359]
Krishnan E. “Inflammation, oxidative stress and lipids: the risk triad for atherosclerosis in gout.” Rheumatology (Oxford, England) (2010). PMID: 20202928 ↗
L5REVIEW_NARRATIVECited in: Complications: Disease-Driven & Treatment-Related - [360]
Cantalejo Moreira M, Veiga Cabello RM, García Díaz V et al.. “Gout, hyperuricaemia, sleep apnoea-hypopnoea syndrome and vascular risk.” Rheumatology (Oxford, England) (2013). PMID: 23418048 ↗
L3OTHERCited in: Complications: Disease-Driven & Treatment-Related - [361]
Reginato AM, Mount DB, Yang I et al.. “The genetics of hyperuricaemia and gout.” Nature reviews. Rheumatology (2012). PMID: 22945592 ↗
L5REVIEW_NARRATIVECited in: Complications: Disease-Driven & Treatment-Related - [362]
Wang H, Mei H, Duan Y et al.. “Efficacy and safety of Jinhuang ointment in treating acute gouty arthritis: a retrospective cohort study.” Frontiers in pharmacology (2025). PMID: 41458967 ↗
L3COHORTCited in: Complications: Disease-Driven & Treatment-Related - [363]
Wang W, Wang SI, Cheng Y et al.. “Febuxostat may decrease the incidence of COVID-19 infection among patients with gout: a retrospective cohort study.” Frontiers in pharmacology (2025). PMID: 41235116 ↗
L3COHORTCited in: Complications: Disease-Driven & Treatment-Related, Special Populations, Pregnancy & Prevention - [364]
Moon KW, Jung SH, Do H et al.. “Cardiovascular risk according to genetic predisposition to gout, lifestyle and metabolic health across prospective European and Korean cohorts.” RMD open (2024). PMID: 39379299 ↗
L2OTHERCited in: Complications: Disease-Driven & Treatment-Related - [365]
Branco JC, Rodrigues AM, Gouveia N et al.. “Prevalence of rheumatic and musculoskeletal diseases and their impact on health-related quality of life, physical function and mental health in Portugal: results from EpiReumaPt- a national health survey.” RMD open (2016). PMID: 26848402 ↗
L4OTHERCited in: Complications: Disease-Driven & Treatment-Related - [366]
Magagnoli J, Cummings TH, Ambati M et al.. “Acute cardiovascular events after discontinuation of xanthine oxidase inhibitors: a cohort study.” Clinical rheumatology (2025). PMID: 41452540 ↗
L3COHORTCited in: Complications: Disease-Driven & Treatment-Related - [367]
Zhang W, Doherty M, Bardin T et al.. “EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).” Annals of the rheumatic diseases (2006). PMID: 16707532 ↗
L1GUIDELINECited in: Prognosis & Natural History - [368]
Dalbeth N, Schauer C, Macdonald P et al.. “Methods of tophus assessment in clinical trials of chronic gout: a systematic literature review and pictorial reference guide.” Annals of the rheumatic diseases (2011). PMID: 21216814 ↗
L2TRIAL_NONRANDOMCited in: Prognosis & Natural History - [369]
Nielsen SM, Bartels EM, Henriksen M et al.. “Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies.” Annals of the rheumatic diseases (2017). PMID: 28866649 ↗
L2SR_OBSCited in: Prognosis & Natural History - [370]
Stamp LK, Chapman P, Frampton C et al.. “Lack of effect of tart cherry concentrate dose on serum urate in people with gout.” Rheumatology (Oxford, England) (2020). PMID: 31891407 ↗
L1RCTCited in: Prognosis & Natural History - [371]
Wang C, Guo K, Dalbeth N et al.. “Impact of adding urine alkalization therapy to xanthine oxidase inhibitor in gout management: a prospective cohort study.” Rheumatology (Oxford, England) (2025). PMID: 39932882 ↗
L2TRIAL_NONRANDOMCited in: Prognosis & Natural History - [372]
Cheng Z, Xu X, Qi H et al.. “Obesity reduces the urate-lowering efficacy among patients with primary gout: a prospective cohort study.” Rheumatology (Oxford, England) (2025). PMID: 39928353 ↗
L2TRIAL_NONRANDOMCited in: Prognosis & Natural History - [373]
Sutaria S, Katbamna R, Underwood M. “Effectiveness of interventions for the treatment of acute and prevention of recurrent gout--a systematic review.” Rheumatology (Oxford, England) (2006). PMID: 16632483 ↗
L1SR_OBSCited in: Prognosis & Natural History, Special Populations, Pregnancy & Prevention - [374]
Araújo F, Cordeiro I, Ramiro S et al.. “Outcomes assessed in trials of gout and accordance with OMERACT-proposed domains: a systematic literature review.” Rheumatology (Oxford, England) (2014). PMID: 25398382 ↗
L1SR_OBSCited in: Prognosis & Natural History - [375]
Zhang T, Pope JE. “Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis.” Rheumatology (Oxford, England) (2017). PMID: 28379501 ↗
L1SR_OBSCited in: Prognosis & Natural History - [376]
Pollyea DA, Stevens BM, Abbott D et al.. “Omacetaxine and azacitidine for untreated patients with myelodysplastic syndromes and excess blasts: a phase I/II clinical trial.” EClinicalMedicine (2025). PMID: 41140451 ↗
L4TRIAL_NONRANDOMCited in: Prognosis & Natural History - [377]
van Durme CM, Wechalekar MD, Buchbinder R et al.. “Non-steroidal anti-inflammatory drugs for acute gout.” The Cochrane database of systematic reviews (2014). PMID: 25225849 ↗
L1SR_OBSCited in: Prognosis & Natural History - [378]
Chalati MD, Shirvankar C, Gore G et al.. “Are Machine Learning methods effective in detecting undiagnosed atrial fibrillation in primary care settings using electronic health records? A systematic review.” PLOS digital health (2025). PMID: 41086202 ↗
L2SR_OBSCited in: Prognosis & Natural History - [379]
Wu J, Han Y, Yao M et al.. “Serum uric acid and the trajectory of cardiometabolic multimorbidity: a prospective study conducted with data from the UK Biobank.” Nutrition journal (2026). PMID: 42063047 ↗
L2COHORTCited in: Prognosis & Natural History - [380]
Yu J, Mi T, Shao Z et al.. “The Outcomes of Patients With Hyperuricemia After Total Knee Arthroplasty: A Retrospective Cohort Study.” Orthopaedic surgery (2025). PMID: 41198532 ↗
L2COHORTCited in: Prognosis & Natural History - [381]
Ghang BZ, Lee JS, Choi J et al.. “Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial.” RMD open (2022). PMID: 35732345 ↗
L2OTHERCited in: Prognosis & Natural History - [382]
Pérez Ruiz F, Richette P, Stack AG et al.. “Failure to reach uric acid target of <0.36 mmol/L in hyperuricaemia of gout is associated with elevated total and cardiovascular mortality.” RMD open (2019). PMID: 31673414 ↗
L2OTHERCited in: Prognosis & Natural History - [383]
Schumacher HR, Evans RR, Saag KG et al.. “Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study.” Arthritis care & research (2012). PMID: 22549879 ↗
L1RCTCited in: Special Populations, Pregnancy & Prevention - [384]
Kawamura Y, Nakaoka H, Nakayama A et al.. “Genome-wide association study revealed novel loci which aggravate asymptomatic hyperuricaemia into gout.” Annals of the rheumatic diseases (2019). PMID: 31289104 ↗
L3SR_OBSCited in: Special Populations, Pregnancy & Prevention - [385]
Schieir O, Tosevski C, Glazier RH et al.. “Incident myocardial infarction associated with major types of arthritis in the general population: a systematic review and meta-analysis.” Annals of the rheumatic diseases (2017). PMID: 28219882 ↗
L2SR_OBSCited in: Special Populations, Pregnancy & Prevention - [386]
Koto R, Nakajima A, Horiuchi H et al.. “Serum uric acid control for prevention of gout flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance claims and medical check-up data in Japan.” Annals of the rheumatic diseases (2021). PMID: 34158371 ↗
L2COHORTCited in: Special Populations, Pregnancy & Prevention - [387]
Latourte A, Soumaré A, Bardin T et al.. “Uric acid and incident dementia over 12 years of follow-up: a population-based cohort study.” Annals of the rheumatic diseases (2017). PMID: 28754803 ↗
L2COHORTCited in: Special Populations, Pregnancy & Prevention - [388]
Kim JH, Yim DH, Choi IA et al.. “Impact of Clinical Association Between Gout and Dementia: A Nationwide Population-Based Cohort Study in Korea.” Arthritis care & research (2022). PMID: 35604886 ↗
L2COHORTCited in: Special Populations, Pregnancy & Prevention - [389]
Mitha E, Schumacher HR, Fouche L et al.. “Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial.” Rheumatology (Oxford, England) (2013). PMID: 23485476 ↗
L1RCTCited in: Special Populations, Pregnancy & Prevention - [390]
Khanna D, Sarkin AJ, Khanna PP et al.. “Minimally important differences of the gout impact scale in a randomized controlled trial.” Rheumatology (Oxford, England) (2011). PMID: 21372003 ↗
L1RCTCited in: Special Populations, Pregnancy & Prevention - [391]
Safiri S, Kolahi AA, Cross M et al.. “Prevalence, Incidence, and Years Lived With Disability Due to Gout and Its Attributable Risk Factors for 195 Countries and Territories 1990-2017: A Systematic Analysis of the Global Burden of Disease Study 2017.” Arthritis & rheumatology (Hoboken, N.J.) (2020). PMID: 32755051 ↗
L2OTHERCited in: Special Populations, Pregnancy & Prevention - [392]
Ji A, Sui Y, Xue X et al.. “Novel Genetic Loci in Early-Onset Gout Derived From Whole-Genome Sequencing of an Adolescent Gout Cohort.” Arthritis & rheumatology (Hoboken, N.J.) (2024). PMID: 39118347 ↗
L4OTHERCited in: Special Populations, Pregnancy & Prevention - [393]
Yun H, Yang S, Chen L et al.. “Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination.” Arthritis & rheumatology (Hoboken, N.J.) (2016). PMID: 26990731 ↗
L2OTHERCited in: Special Populations, Pregnancy & Prevention - [394]
Kim HW, Kang M, Lim H et al.. “Association between colchicine use and adverse cardiovascular events in patients with gout: a nationwide nested case-control study.” Rheumatology (Oxford, England) (2025). PMID: 39392785 ↗
L3CASE_CONTROLCited in: Special Populations, Pregnancy & Prevention - [395]
Rai SK, Aviña-Zubieta JA, McCormick N et al.. “Trends in Gout and Rheumatoid Arthritis Hospitalizations in Canada From 2000 to 2011.” Arthritis care & research (2017). PMID: 27565008 ↗
L2OTHERCited in: Special Populations, Pregnancy & Prevention - [396]
George M, Pullman-Mooar S, Hussain F et al.. “Evaluating appropriate use of prophylactic colchicine for gout flare prevention.” Arthritis care & research (2014). PMID: 24376081 ↗
L4OTHERCited in: Special Populations, Pregnancy & Prevention - [397]
Zhu H, Yi X, He M et al.. “Childhood Obesity and Age-Related Diseases: A Systematic Review and Meta-Analysis of Mendelian Randomization Evidence.” Pediatric obesity (2025). PMID: 41236085 ↗
L2SR_OBSCited in: Special Populations, Pregnancy & Prevention - [398]
Ben Salem C, Slim R, Fathallah N et al.. “Drug-induced hyperuricaemia and gout.” Rheumatology (Oxford, England) (2017). PMID: 27498351 ↗
L5REVIEW_NARRATIVECited in: Special Populations, Pregnancy & Prevention - [399]
Dalbeth N, Merriman T. “Crystal ball gazing: new therapeutic targets for hyperuricaemia and gout.” Rheumatology (Oxford, England) (2008). PMID: 19109320 ↗
L5REVIEW_NARRATIVECited in: Special Populations, Pregnancy & Prevention - [400]
Jatuworapruk K, Grainger R, Dalbeth N et al.. “The GOUT-36 prediction rule for inpatient gout flare in people with comorbid gout: derivation and external validation.” Rheumatology (Oxford, England) (2022). PMID: 34297058 ↗
L2OTHERCited in: Special Populations, Pregnancy & Prevention - [401]
Wu C, Zhang H, Xia J et al.. “Shift work, genetic risk, and incident gout: a prospective cohort study in the UK Biobank.” Archives of public health = Archives belges de sante publique (2026). PMID: 41840709 ↗
L2COHORTCited in: Special Populations, Pregnancy & Prevention - [402]
Singh JA, Cleveland JD. “Gout and the risk of incident atrial fibrillation in older adults: a study of US Medicare data.” RMD open (2018). PMID: 30018808 ↗
L2OTHERCited in: Special Populations, Pregnancy & Prevention